Document

0000010795-19-000043.txt : 20191105 0000010795-19-000043.hdr.sgml : 20191105 20191105061500 ACCESSION NUMBER: 0000010795-19-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20191105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191105 DATE AS OF CHANGE: 20191105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-04802 FILM NUMBER: 191191643 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 8-K 1 a093020198-k.htm 8-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 5, 2019



BECTON, DICKINSON AND COMPANY
(Exact Name of Registrant as Specified in Its Charter)

New Jersey
(State or Other Jurisdiction of Incorporation)



001-4802			22-0760120
(Commission File Number)			(IRS Employer Identification No.)

1 Becton Drive,	Franklin Lakes,	New Jersey	07417-1880
(Address of Principal Executive Offices)			(Zip Code)



	(201)	847-6800
(Registrant’s Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)



☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $1.00	BDX	New York Stock Exchange
Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A	BDXA	New York Stock Exchange
1.000% Notes due December 15, 2022	BDX22A	New York Stock Exchange
1.900% Notes due December 15, 2026	BDX26	New York Stock Exchange
1.401% Notes due May 24, 2023	BDX23A	New York Stock Exchange
3.020% Notes due May 24, 2025	BDX25	New York Stock Exchange
0.174% Notes due June 4, 2021	BDX/21	New York Stock Exchange
0.632% Notes due June 4, 2023	BDX/23A	New York Stock Exchange
1.208% Notes due June 4, 2026	BDX/26A	New York Stock Exchange



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 5, 2019, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter and full fiscal year ending September 30, 2019. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

•

Currency-Neutral Revenue Growth. We present revenue growth rates for our fourth quarter and 2019 fiscal year over the corresponding prior periods, and our estimated revenue growth for our 2020 fiscal year, after eliminating the effect of foreign currency translation, which can fluctuate from period to period. Management believes these adjustments help investors to better understand the underlying performance (and anticipated performance) of BD and evaluate such performance in comparison to the prior periods.

•

Comparable Revenue Growth. We present revenue growth for our fourth quarter and our 2019 fiscal year on a “comparable”, currency-neutral basis, which includes the results of C.R. Bard, Inc. ("Bard") in the prior year period, as applicable, and adjustments to (1) eliminate revenues relating to divestitures, (2) reflect cumulative customer rebate and incentive fees relating to fiscal year 2018, (3) account for the reclassification of certain royalties previously reported by Bard as revenues; and (4) eliminate intercompany revenues. We believe these measures help investors better understand and evaluate the BD's underlying performance for the periods presented by adjusting for items that effect year-to-year comparability. Fiscal year 2019 adjusted comparable revenues are presented for illustrative purposes only, and are not necessarily indicative of the operating results or financial position that would have occurred if the Bard acquisition had been consummated at the beginning of our 2018 fiscal year.

•

Adjusted Earnings Per Share. We present diluted earnings per share (“EPS”) for our fourth quarter and 2019 fiscal year, and the corresponding prior periods, after eliminating items that we believe are not part of our ordinary operations and affect the comparability of the periods presented (“adjusted EPS”). Adjusted EPS includes adjustments for, as applicable, purchase accounting adjustments, acquisition-related transaction, integration and restructuring costs, the impact of the extinguishment of long-term debt, certain regulatory costs, divestiture-related gains, hurricane-related items, certain litigation and recall charges and costs, certain asset impairments, the financing impacts associated with, and the dilutive impact of shares issued to fund, the Bard acquisition, and the impact of U.S. tax reform. We believe adjustments for these items allow investors to better understand the underlying operating results of BD and facilitate comparisons between the periods shown. We also show the growth in adjusted EPS compared to the prior year period after eliminating the impact of foreign currency translation, which can fluctuate from period to period, to further enable investors to evaluate BD’s underlying earnings performance compared to the prior periods. Details regarding these adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1.

We also present our estimated adjusted EPS growth for our 2020 fiscal year after adjusting for the anticipated impact of foreign currency translation. Management believes that this adjustment allows investors to better evaluate BD’s anticipated underlying earnings performance for our 2020 fiscal year in relation to our underlying 2019 fiscal year performance.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods and to the performance of peer companies. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis in addition to our GAAP results, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability. However, non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Also, our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated November 5, 2019, which is furnished pursuant to Item 2.02

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY

(Registrant)



By:	/s/ Gary DeFazio
	Gary DeFazio
	Senior Vice President and Corporate Secretary

Date: November 5, 2019

EX-99.1 2 ex99109302019.htm EXHIBIT 99.1 Exhibit

Exhibit 99.1

1 Becton Drive

Franklin Lakes, NJ 07417

www.bd.com

Contact:

Monique N. Dolecki, Investor Relations - 201-847-5378

Kristen Cardillo, Corporate Communications - 201-847-5657

BD ANNOUNCES RESULTS FOR 2019 FOURTH FISCAL QUARTER AND FULL YEAR;

PROVIDES FISCAL 2020 GUIDANCE


•	As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent.


•	On a comparable, currency-neutral basis, revenues increased 5.1 percent for the full fiscal year.


•	As reported, full fiscal year diluted earnings per share of $3.89 increased 548.3 percent.


•	As adjusted, full fiscal year diluted earnings per share of $11.68 increased 6.1 percent, or 11.9 percent on a currency-neutral basis.


•	The company expects full fiscal year 2020 revenues to increase 4.0 to 4.5 percent as reported, or 5.0 to 5.5 percent on a currency-neutral basis.

•

As adjusted, the company expects full fiscal year 2020 diluted earnings per share to be between $12.50 and $12.65, resulting in growth of approximately 9.5 to 11.0 percent on a currency-neutral basis. This represents growth of approximately 7.0 to 8.5 percent including the estimated unfavorable impact of foreign currency. Adjusted diluted earnings per share guidance includes an adverse impact of approximately 500 basis points related to the expiration of the Gore royalty.

Franklin Lakes, NJ (November 5, 2019) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30, 2019. This represents an increase of 4.1 percent over the prior-year period. On a comparable, currency-neutral basis, revenues increased 6.2 percent over the prior-year period.

For the full fiscal year ended September 30, 2019, revenues of $17.290 billion increased 8.2 percent from the prior-year period. On a comparable, currency-neutral basis, full fiscal year revenues of $17.281 billion grew 5.1 percent.

“We are very proud of our accomplishments in fiscal year 2019. Our performance this year demonstrates our ability to overcome multiple headwinds and deliver on our financial and operational goals,” said Vincent A. Forlenza, chairman and CEO. “We enter fiscal 2020 with continued optimism. There are significant opportunities ahead to leverage the capabilities we’ve built to better serve our customers and their patients around the world. It has been a privilege to lead BD and our global team of talented associates. I’m confident that under Tom Polen’s leadership the company will further accelerate its impact as BD enters its next phase of value creation.”

Fourth Quarter and Twelve-Month Fiscal 2019 Operating Results

As reported, diluted earnings per share for the fourth quarter were $0.41, compared with $(0.64) in the prior-year period. This represents an increase of 164.1 percent. Adjusted diluted earnings per share were $3.31, compared with $2.93 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 13.0 percent, or 12.3 percent on a currency-neutral basis.

For the twelve-month period ended September 30, 2019, as reported, diluted earnings per share were $3.89, compared with $0.60 in the prior-year period. This represents an increase of 548.3 percent. Adjusted diluted earnings per share were $11.68, compared with $11.01 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 6.1 percent, or 11.9 percent on a currency-neutral basis.

Segment Results

In the BD Medical segment, as reported, worldwide revenues for the quarter of $2.437 billion increased 3.9 percent over the prior-year period, or 5.3 percent on a currency-neutral basis. The segment’s results were driven by performance in the Medication Management Solutions and Pharmaceutical Systems units.

For the twelve-month period ended September 30, 2019, BD Medical revenues were $9.064 billion as reported, which represents an increase of 5.2 percent over the prior-year period. On a comparable, currency-neutral basis, BD Medical revenues increased 5.1 percent.

In the BD Life Sciences segment, as reported, worldwide revenues for the quarter of $1.134 billion increased 2.3 percent over the prior-year period. On a comparable, currency-neutral basis, revenues increased 6.9 percent. Revenue growth was driven by performance in the Diagnostic Systems and Biosciences units.

For the twelve-month period ended September 30, 2019, BD Life Sciences revenues were $4.300 billion as reported, which represents a decrease of 0.7 percent from the prior-year period. On a comparable, currency-neutral basis, BD Life Sciences revenues of $4.291 billion increased 4.9 percent.

In the BD Interventional segment, as reported, worldwide revenues for the quarter of $1.013 billion increased 6.9 percent over the prior-year period, or 7.7 percent on a currency-neutral basis. The segment's results were driven by performance in the Surgery and Urology and Critical Care units.

For the twelve-month period ended September 30, 2019, BD Interventional revenues were $3.926 billion as reported, which represents an increase of 29.3 percent over the prior-year period. On a comparable, currency-neutral basis, BD Interventional revenues increased 5.5 percent.

Geographic Results

As reported, fourth quarter revenues in the U.S. of $2.562 billion increased 4.6 percent over the prior-year period. On a comparable basis, U.S. revenues increased 4.9 percent over the prior-year period. Growth in the U.S. was driven by the Medication Management Solutions unit within the BD Medical segment, the Biosciences unit within the BD Life Sciences segment, and the Surgery and Urology and Critical Care units with the BD Interventional segment.

As reported, revenues outside of the U.S. of $2.022 billion increased 3.5 percent over the prior-year period. On a comparable, currency-neutral basis, revenues outside of the U.S. increased 7.9 percent over the prior-year period. International revenue growth was driven by performance in Europe, Asia Pacific and EMA.

For the twelve-month period ended September 30, 2019, U.S. revenues were $9.730 billion as reported, which represents an increase of 11.0 percent over the prior-year period. On a comparable basis, U.S. revenues of $9.726 billion increased 4.5 percent over the prior-year period. As reported, revenues outside of the U.S. of $7.560 billion increased 4.8 percent over the prior-year period. On a comparable, currency-neutral basis, revenues outside the U.S. of $7.555 billion increased 5.9 percent over the prior-year period.

Fiscal 2020 Outlook for Full Year

The company expects full fiscal year 2020 revenues to increase 4.0 to 4.5 percent as reported, or 5.0 to 5.5 percent on a currency-neutral basis.

The company expects full fiscal year 2020 adjusted diluted earnings per share to be between $12.50 and $12.65. This represents growth of approximately 9.5 to 11.0 percent on a currency-neutral basis over fiscal 2019 adjusted diluted earnings per share of $11.68, or growth of approximately 7.0 to 8.5 percent including the estimated unfavorable impact of foreign currency. Adjusted diluted earnings per share guidance includes an adverse impact of approximately 500 basis points related to the expiration of the Gore royalty.

Adjusted diluted earnings per share for fiscal 2020 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking non-GAAP earnings guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of BD's financial performance.

Conference Call Information

A conference call regarding BD’s fourth quarter results will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, November 5, 2019. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, November 12, 2019, confirmation number 5994332.

Non-GAAP Financial Measures/Financial Tables

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

All “comparable” basis revenue growth rates relating to fiscal year 2019 presented throughout this release include, where applicable, the results of C. R. Bard, Inc. (“Bard”) in the prior-year period, and also include adjustments for certain items as detailed in the attached tables. Beginning in the second quarter of fiscal year 2018, the Company's organizational structure was based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Interventional segment was added upon the Company's completion of its acquisition of Bard and includes the majority of Bard’s product offerings and certain product offerings that were previously reported in the Medical segment. Certain of Bard's product offerings are included under the Company's Medical segment, specifically within the Medication Delivery Solutions unit, which was formerly the Medical segment's Medication and Procedural Solutions unit. Current and prior-year adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs; transactional and product related impacts; and the loss on debt extinguishment. We also provide these measures on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. Reconciliations of these amounts to the most directly comparable GAAP measures are included in the tables at the end of this release.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.

***

This press release, including the section entitled “Fiscal 2020 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These factors include, but are not limited to risks relating to the integration of the C.R. Bard operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; new or changing laws and regulations impacting our business (including the imposition of tariffs or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; fluctuations in

costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; legislative or regulatory changes to the U.S. or foreign healthcare systems, potential cuts in governmental healthcare spending, or governmental or private measures to contain healthcare costs, including changes in pricing and reimbursement policies, each of which could result in reduced demand for our products or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic conditions, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers’ ability to provide products needed for our operations; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; interruptions in our supply chain or manufacturing processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; product efficacy or safety concerns resulting in product recalls or actions being taken by the FDA or other regulators (including the potential ongoing impact of the FDA letters regarding the use of drug-coated balloons); our ability to successfully integrate any businesses we acquire; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)



	Three Months Ended September 30,
	2019			2018			% Change
REVENUES	$	4,584		$	4,402		4.1

Cost of products sold	2,318			2,309			0.4
Selling and administrative expense	1,094			1,102			(0.7	)
Research and development expense	270			276			(2.4	)
Acquisitions and other restructurings	199			139			42.7
Other operating expense, net	592			—			100.0
TOTAL OPERATING COSTS AND EXPENSES	4,473			3,826			16.9
OPERATING INCOME	111			576			(80.8	)

Interest expense	(141		)	(181		)	(21.9	)
Interest income	4			9			(51.2	)
Other income, net	11			10			6.7
(LOSS) INCOME BEFORE INCOME TAXES	(15		)	415			(103.5	)
Income tax (benefit) provision	(164		)	550			(129.9	)
NET INCOME (LOSS)	150			(135		)	211.0
Preferred stock dividends	(38		)	(38		)	—
NET INCOME (LOSS) APPLICABLE TO COMMON SHAREHOLDERS	$	112		$	(173	)	164.7

EARNINGS PER SHARE
Basic Earnings (Loss) per Share	$	0.41		$	(0.64	)	164.1
Diluted Earnings (Loss) per Share	$	0.41		$	(0.64	)	164.1

AVERAGE SHARES OUTSTANDING (in thousands)
Basic	270,610			268,500
Diluted	274,959			268,500

Page 1

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)



	Twelve Months Ended September 30,
	2019			2018			% Change
REVENUES	$	17,290		$	15,983		8.2

Cost of products sold	9,002			8,714			3.3
Selling and administrative expense	4,332			4,016			7.9
Research and development expense	1,062			1,004			5.8
Acquisitions and other restructurings	480			740			(35.1	)
Other operating expense, net	654			—			100.0
TOTAL OPERATING COSTS AND EXPENSES	15,530			14,474			7.3
OPERATING INCOME	1,760			1,509			16.6

Interest expense	(639		)	(706		)	(9.4	)
Interest income	12			65			(81.0	)
Other income, net	30			305			(90.3	)
INCOME BEFORE INCOME TAXES	1,163			1,173			(0.9	)
Income tax (benefit) provision	(57		)	862			(106.6	)
NET INCOME	1,220			311			292.4
Preferred stock dividends	(152		)	(152		)	—
NET INCOME APPLICABLE TO COMMON SHAREHOLDERS	$	1,069		$	159		570.6

EARNINGS PER SHARE
Basic Earnings per Share	$	3.96		$	0.62		538.7
Diluted Earnings per Share	$	3.89		$	0.60		548.3

AVERAGE SHARES OUTSTANDING (in thousands)
Basic	269,943			258,354
Diluted	274,775			264,621

Page 2

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in millions)



	September 30, 2019		September 30, 2018
	(Unaudited)
	Preliminary
ASSETS
Cash and equivalents	$	536	$	1,140
Restricted cash	54		96
Short-term investments	30		17
Trade receivables, net	2,335		2,319
Inventories	2,579		2,451
Assets held for sale	—		137
Prepaid expenses and other	1,110		1,251
TOTAL CURRENT ASSETS	6,644		7,411
Property, plant and equipment, net	5,659		5,375
Goodwill and other intangibles, net	38,463		40,041
Other Assets	1,075		1,078
TOTAL ASSETS	$	51,842	$	53,904
LIABILITIES AND SHAREHOLDERS' EQUITY
Short-term debt	$	1,309	$	2,601
Other current liabilities	4,289		4,615
Long-term debt	18,081		18,894
Long-term employee benefit obligations	1,272		1,056
Deferred income taxes and other	5,714		5,743
Shareholders’ equity	21,177		20,994
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	51,842	$	53,904

The preliminary balance sheet is estimated based on the Company's current information.

Page 3

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in millions)



	Twelve Months Ended September 30,
	2019			2018
	(Unaudited)
	Preliminary
OPERATING ACTIVITIES
Net income	$	1,220		$	311
Depreciation and amortization	2,253			1,978
Change in operating assets and liabilities and other, net	(143		)	576
NET CASH PROVIDED BY OPERATING ACTIVITIES	3,330			2,865
INVESTING ACTIVITIES
Capital expenditures	(957		)	(895		)
Acquisitions of businesses, net of cash acquired	—			(15,155		)
Proceeds from divestitures, net	477			534
Other, net	(261		)	(217		)
NET CASH USED FOR INVESTING ACTIVITIES	(741		)	(15,733		)
FINANCING ACTIVITIES
Change in credit facility borrowings	485			—
Proceeds from long-term debt and term loans	2,224			5,086
Payments of debt and term loans	(4,744		)	(3,996		)
Dividends paid	(984		)	(927		)
Other, net	(205		)	(220		)
NET CASH USED FOR FINANCING ACTIVITIES	(3,223		)	(58		)
Effect of exchange rate changes on cash and equivalents and restricted cash	(12		)	(17		)
NET DECREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH	(646		)	(12,943		)
OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH	1,236			14,179
CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH	$	590		$	1,236

The preliminary cash flow is estimated based on the Company's current information.

Page 4

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Three Months Ended September 30,

(Unaudited; Amounts in millions)



	A		B		C=(A-B)/B
	2019		2018		% Change
BD MEDICAL
Medication Delivery Solutions	$	520	$	512	1.5
Medication Management Solutions	573		542		5.6
Diabetes Care	151		149		1.3
Pharmaceutical Systems	123		118		4.2
TOTAL	$	1,366	$	1,322	3.4

BD LIFE SCIENCES
Preanalytical Systems	$	200	$	196	2.0
Diagnostic Systems	162		159		1.8
Biosciences	140		125		11.5
TOTAL	$	502	$	481	4.4

BD INTERVENTIONAL
Surgery	$	279	$	259	7.8
Peripheral Intervention	207		201		3.3
Urology and Critical Care	207		186		11.3
TOTAL	$	693	$	646	7.4

TOTAL UNITED STATES	$	2,562	$	2,448	4.6

Page 5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



								D=(A-B)/B		E=(A-B-C)/B
	A		B		C			% Change
	2019		2018		FX Impact			Reported		FXN
BD MEDICAL
Medication Delivery Solutions	$	468	$	454	$	(13	)	2.9		5.8
Medication Management Solutions	161		149		(6		)	7.5		11.4
Diabetes Care	141		135		(3		)	3.9		6.4
Pharmaceutical Systems	302		285		(10		)	5.8		9.3
TOTAL	$	1,071	$	1,025	$	(33	)	4.5		7.7

BD LIFE SCIENCES
Preanalytical Systems	$	193	$	197	$	(6	)	(1.8	)	1.3
Diagnostic Systems	247		224		(6		)	10.1		12.6
Biosciences	192		206		(4		)	(6.8	)	(4.8	)
TOTAL	$	632	$	627	$	(16	)	0.8		3.3

BD INTERVENTIONAL
Surgery	$	76	$	69	$	(2	)	10.6		13.3
Peripheral Intervention	154		148		(4		)	3.9		6.7
Urology and Critical Care	90		85		(1		)	5.1		6.8
TOTAL	$	319	$	302	$	(8	)	5.7		8.3

TOTAL INTERNATIONAL	$	2,022	$	1,954	$	(56	)	3.5		6.4

Page 6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



								D=(A-B)/B	E=(A-B-C)/B
	A		B		C			% Change
	2019		2018		FX Impact			Reported	FXN
BD MEDICAL
Medication Delivery Solutions	$	988	$	967	$	(13	)	2.2	3.5
Medication Management Solutions	733		692		(6		)	6.0	6.8
Diabetes Care	292		285		(3		)	2.5	3.7
Pharmaceutical Systems	425		403		(10		)	5.3	7.8
TOTAL	$	2,437	$	2,346	$	(33	)	3.9	5.3

BD LIFE SCIENCES
Preanalytical Systems	$	393	$	393	$	(6	)	0.1	1.6
Diagnostic Systems	409		384		(6		)	6.6	8.1
Biosciences	332		331		(4		)	0.1	1.4
TOTAL	$	1,134	$	1,108	$	(16	)	2.3	3.8

BD INTERVENTIONAL
Surgery	$	355	$	328	$	(2	)	8.3	8.9
Peripheral Intervention	361		348		(4		)	3.5	4.7
Urology and Critical Care	297		271		(1		)	9.3	9.9
TOTAL	$	1,013	$	948	$	(8	)	6.9	7.7

TOTAL REVENUES	$	4,584	$	4,402	$	(56	)	4.1	5.4

Page 7

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)



	A		B		C=(A-B)/B
	2019		2018		% Change
BD MEDICAL
Medication Delivery Solutions	$	2,048	$	1,892	8.3
Medication Management Solutions	2,104		1,957		7.5
Diabetes Care	573		564		1.5
Pharmaceutical Systems	392		357		9.7
TOTAL	$	5,116	$	4,770	7.3

BD LIFE SCIENCES
Preanalytical Systems	$	774	$	761	1.7
Diagnostic Systems	672		678		(0.8	)
Biosciences	485		475		2.0
TOTAL	$	1,931	$	1,914	0.9

BD INTERVENTIONAL
Surgery	$	1,098	$	946	16.0
Peripheral Intervention	787		594		32.5
Urology and Critical Care	797		544		46.6
TOTAL	$	2,682	$	2,084	28.7

TOTAL UNITED STATES	$	9,730	$	8,768	11.0

Page 8

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



								D=(A-B)/B		E=(A-B-C)/B
	A		B		C			% Change
	2019		2018		FX Impact			Reported		FXN
BD MEDICAL
Medication Delivery Solutions	$	1,811	$	1,752	$	(97	)	3.4		8.9
Medication Management Solutions	525		513		(26		)	2.4		7.5
Diabetes Care	538		541		(26		)	(0.5	)	4.3
Pharmaceutical Systems	1,073		1,040		(47		)	3.1		7.6
TOTAL	$	3,947	$	3,846	$	(196	)	2.6		7.7

BD LIFE SCIENCES
Preanalytical Systems	$	784	$	792	$	(46	)	(1.0	)	4.8
Diagnostic Systems	875		858		(39		)	1.9		6.5
Biosciences	709		766		(27		)	(7.4	)	(3.8	)
TOTAL	$	2,368	$	2,416	$	(113	)	(2.0	)	2.7

BD INTERVENTIONAL
Surgery	$	299	$	245	$	(13	)	22.0		27.5
Peripheral Intervention	602		451		(29		)	33.5		40.0
Urology and Critical Care	342		256		(12		)	33.5		38.4
TOTAL	$	1,244	$	953	$	(55	)	30.6		36.3

TOTAL INTERNATIONAL	$	7,560	$	7,215	$	(363	)	4.8		9.8

Page 9

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



								D=(A-B)/B		E=(A-B-C)/B
	A		B		C			% Change
	2019		2018		FX Impact			Reported		FXN
BD MEDICAL
Medication Delivery Solutions	$	3,859	$	3,644	$	(97	)	5.9		8.6
Medication Management Solutions	2,629		2,470		(26		)	6.4		7.5
Diabetes Care	1,110		1,105		(26		)	0.5		2.9
Pharmaceutical Systems	1,465		1,397		(47		)	4.8		8.2
TOTAL	$	9,064	$	8,616	$	(196	)	5.2		7.5

BD LIFE SCIENCES
Preanalytical Systems	$	1,558	$	1,553	$	(46	)	0.3		3.3
Diagnostic Systems	1,547		1,536		(39		)	0.7		3.3
Biosciences	1,194		1,241		(27		)	(3.8	)	(1.6	)
TOTAL	$	4,300	$	4,330	$	(113	)	(0.7	)	1.9

BD INTERVENTIONAL
Surgery	$	1,397	$	1,192	$	(13	)	17.3		18.4
Peripheral Intervention	1,389		1,045		(29		)	33.0		35.8
Urology and Critical Care	1,140		800		(12		)	42.4		44.0
TOTAL	$	3,926	$	3,037	$	(55	)	29.3		31.1

TOTAL REVENUES	$	17,290	$	15,983	$	(363	)	8.2		10.5

Page 10

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - UNITED STATES

Three Months Ended September 30,

(Unaudited; Amounts in millions)




	A		B		C			D=B+C		E=(A-D)/D
	BD Reported		BD Reported		Divestiture Adjustments (a)			Comparable		Comparable % Change
	2019		2018		Divestiture Adjustments (a)			2018		Comparable % Change
BD MEDICAL
Medication Delivery Solutions	$	520	$	512	$	—		$	512	1.5
Medication Management Solutions	573		542		—			542		5.6
Diabetes Care	151		149		—			149		1.3
Pharmaceutical Systems	123		118		—			118		4.2
TOTAL	$	1,366	$	1,322	$	—		$	1,322	3.4

BD LIFE SCIENCES
Preanalytical Systems	$	200	$	196	$	—		$	196	2.0
Diagnostic Systems	162		159		—			159		1.8
Biosciences	140		125		(6		)	119		16.9
TOTAL	$	502	$	481	$	(6	)	$	475	5.7

BD INTERVENTIONAL
Surgery	$	279	$	259	$	—		$	259	7.8
Peripheral Intervention	207		201		—			201		3.3
Urology and Critical Care	207		186		—			186		11.3
TOTAL	$	693	$	646	$	—		$	646	7.4

TOTAL UNITED STATES	$	2,562	$	2,448	$	(6	)	$	2,442	4.9


(a)	Amounts include adjustments for BD's divestiture of its Advanced Bioprocessing business.

Page 11

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - INTERNATIONAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)




	A		B		C			D=B+C		E			F=(A-D-E)/D
	BD Reported		BD Reported		Divestiture Adjustments (a)			Comparable		FX Impact (b)			FXN % Change
	2019		2018		Divestiture Adjustments (a)			2018		FX Impact (b)			FXN % Change
BD MEDICAL
Medication Delivery Solutions	$	468	$	454	$	—		$	454	$	(14	)	6.0
Medication Management Solutions	161		149		—			149		(6		)	11.4
Diabetes Care	141		135		—			135		(4		)	6.6
Pharmaceutical Systems	302		285		—			285		(10		)	9.3
TOTAL	$	1,071	$	1,025	$	—		$	1,025	$	(34	)	7.8

BD LIFE SCIENCES
Preanalytical Systems	$	193	$	197	$	—		$	197	$	(7	)	1.9
Diagnostic Systems	247		224		—			224		(7		)	13.2
Biosciences	192		206		(23		)	183		(5		)	7.7
TOTAL	$	632	$	627	$	(23	)	$	604	$	(19	)	7.8

BD INTERVENTIONAL
Surgery	$	76	$	69	$	—		$	69	$	(2	)	13.3
Peripheral Intervention	154		148		—			148		(4		)	6.7
Urology and Critical Care	90		85		—			85		(1		)	6.8
TOTAL	$	319	$	302	$	—		$	302	$	(8	)	8.3

TOTAL INTERNATIONAL	$	2,022	$	1,954	$	(23	)	$	1,931	$	(60	)	7.9


(a)	Amounts include adjustments for BD's divestiture of its Advanced Bioprocessing business.

(b)

Under U.S. generally accepted accounting principles and as a result of Argentina’s highly inflationary economy, the functional currency of the Company's operations in Argentina was the U.S. dollar for the quarter ended September 30, 2019. The total foreign currency translation impact above includes $4 million that was calculated by comparing local currency revenues in Argentina for the quarter ended September 30, 2019, translated using the prior-period exchange rate, to the reported U.S. dollar revenues for this same period.

Page 12

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



	A		B		C			D=B+C		E			F=(A-D-E)/D
	BD Reported		BD Reported		Divestiture Adjustments (a)			Comparable		FX Impact (b)			FXN % Change
	2019		2018		Divestiture Adjustments (a)			2018		FX Impact (b)			FXN % Change
BD MEDICAL
Medication Delivery Solutions	$	988	$	967	$	—		$	967	$	(14	)	3.6
Medication Management Solutions	733		692		—			692		(6		)	6.8
Diabetes Care	292		285		—			285		(4		)	3.8
Pharmaceutical Systems	425		403		—			403		(10		)	7.8
TOTAL	$	2,437	$	2,346	$	—		$	2,346	$	(34	)	5.3

BD LIFE SCIENCES
Preanalytical Systems	$	393	$	393	$	—		$	393	$	(7	)	1.9
Diagnostic Systems	409		384		—			384		(7		)	8.4
Biosciences	332		331		(29		)	302		(5		)	11.4
TOTAL	$	1,134	$	1,108	$	(29	)	$	1,079	$	(19	)	6.9

BD INTERVENTIONAL
Surgery	$	355	$	328	$	—		$	328	$	(2	)	8.9
Peripheral Intervention	361		348		—			348		(4		)	4.7
Urology and Critical Care	297		271		—			271		(1		)	9.9
TOTAL	$	1,013	$	948	$	—		$	948	$	(8	)	7.7

TOTAL REVENUES	$	4,584	$	4,402	$	(29	)	$	4,373	$	(60	)	6.2


(a)	Amounts include adjustments for BD's divestiture of its Advanced Bioprocessing business.

(b)

Page 13

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - UNITED STATES

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)



	A		B			C=A+B		D		E		F			G			H=D+E+F+G		I=(C-H)/H
	BD Reported		Divestiture Adjustments (a)			Comparable		BD Reported		Bard Q1 (b)		Intercompany Adjustment (c)			Divestiture and Other Adjustments (a)			Comparable		Comparable % Change
	2019		Divestiture Adjustments (a)			2019		2018		2018		Intercompany Adjustment (c)			Divestiture and Other Adjustments (a)			2018		Comparable % Change
BD MEDICAL
Medication Delivery Solutions	$	2,048	$	—		$	2,048	$	1,892	$	145	$	(3	)	$	(9	)	$	2,025	1.2
Medication Management Solutions	2,104		—			2,104		1,957		—		—			—			1,957		7.5
Diabetes Care	573		—			573		564		—		—			—			564		1.5
Pharmaceutical Systems	392		—			392		357		—		—			—			357		9.7
TOTAL	$	5,116	$	—		$	5,116	$	4,770	$	145	$	(3	)	$	(9	)	$	4,903	4.4

BD LIFE SCIENCES
Preanalytical Systems	$	774	$	—		$	774	$	761	$	—	$	—		$	(12	)	$	749	3.4
Diagnostic Systems	672		—			672		678		—		—			—			678		(0.8	)
Biosciences	485		(4		)	481		475		—		—			(39		)	436		10.3
TOTAL	$	1,931	$	(4	)	$	1,928	$	1,914	$	—	$	—		$	(51	)	$	1,862	3.5

BD INTERVENTIONAL
Surgery	$	1,098	$	—		$	1,098	$	946	$	105	$	—		$	(15	)	$	1,036	6.0
Peripheral Intervention	787		—			787		594		188		—			—			782		0.7
Urology and Critical Care	797		—			797		544		177		—			—			721		10.6
TOTAL	$	2,682	$	—		$	2,682	$	2,084	$	470	$	—		$	(15	)	$	2,539	5.6

TOTAL UNITED STATES	$	9,730	$	(4	)	$	9,726	$	8,768	$	614	$	(3	)	$	(75	)	$	9,304	4.5

(a)

The amounts for the twelve months ended September 30, 2019 and 2018 include adjustments for BD's divestiture of its Advanced Bioprocessing business. The amounts for the twelve months ended September 30, 2018 also include adjustments for BD's divestitures of its soft tissue core needle biopsy product line and Bard's divestiture of its Aspira® product line. Additionally, Medication Delivery Solutions and Preanalytical Systems results for the twelve months ended September 30, 2019 included a total of $21 million in cumulative customer rebate and incentive fees relating to fiscal year 2018. Accordingly, to ensure comparability of revenue growth, the results for the twelve months ended September 30, 2018 have been adjusted to reflect these cumulative fees. The Company records rebate and customer incentive fees as a reduction to revenue.


(b)	Amounts represent revenues for the quarter ended December 31, 2017. BD reported a Gore royalty amount, which was previously reported as revenues by Bard, as non-operating income in the current-year period.


(c)	Represents the elimination of revenues from the Medication Delivery Solutions unit which BD previously recognized from Bard as third-party revenues and that would be treated as intercompany revenues in the current-year period.

Page 14

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - INTERNATIONAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



	A		B			C=A+B		D		E		F			G=D+E+F		H			I=(C-G-H)/G
	BD Reported		Divestiture Adjustments (a)			Comparable		BD Reported		Bard Q1 (b)		Divestiture Adjustments (a)			Comparable		FX Impact (c)			FXN % Change
	2019		Divestiture Adjustments (a)			2019		2018		2018		Divestiture Adjustments (a)			2018		FX Impact (c)			FXN % Change
BD MEDICAL
Medication Delivery Solutions	$	1,811	$	—		$	1,811	$	1,752	$	68	$	—		$	1,821	$	(101	)	5.0
Medication Management Solutions	525		—			525		513		—		—			513		(26		)	7.5
Diabetes Care	538		—			538		541		—		—			541		(28		)	4.6
Pharmaceutical Systems	1,073		—			1,073		1,040		—		—			1,040		(47		)	7.6
TOTAL	$	3,947	$	—		$	3,947	$	3,846	$	68	$	—		$	3,915	$	(202	)	6.0

BD LIFE SCIENCES
Preanalytical Systems	$	784	$	—		$	784	$	792	$	—	$	—		$	792	$	(52	)	5.5
Diagnostic Systems	875		—			875		858		—		—			858		(46		)	7.3
Biosciences	709		(5		)	704		766		—		(67		)	699		(30		)	5.1
TOTAL	$	2,368	$	(5	)	$	2,363	$	2,416	$	—	$	(67	)	$	2,350	$	(129	)	6.1

BD INTERVENTIONAL
Surgery	$	299	$	—		$	299	$	245	$	49	$	(3	)	$	291	$	(13	)	7.5
Peripheral Intervention	602		—			602		451		146		—			597		(29		)	5.8
Urology and Critical Care	342		—			342		256		90		—			347		(12		)	2.4
TOTAL	$	1,244	$	—		$	1,244	$	953	$	285	$	(3	)	$	1,235	$	(55	)	5.2

TOTAL INTERNATIONAL	$	7,560	$	(5	)	$	7,555	$	7,215	$	353	$	(70	)	$	7,499	$	(386	)	5.9


(a)	The amounts for the twelve months ended September 30, 2019 and 2018 include adjustments for BD's divestiture of its Advanced Bioprocessing business. The amounts for the twelve months ended September 30, 2018 also include adjustments for BD's divestitures of its soft tissue core needle biopsy product line and Bard's divestiture of its Aspira® product line.


(b)	Amounts represent revenues for the quarter ended December 31, 2017.

(c)

Under U.S. generally accepted accounting principles and as a result of Argentina’s highly inflationary economy, the functional currency of the Company's operations in Argentina was the U.S. dollar for the twelve months ended September 30, 2019. The total foreign currency translation impact above includes $22 million that was calculated by comparing local currency revenues in Argentina for the twelve months ended September 30, 2019, translated using the prior-period exchange rate, to the reported U.S. dollar revenues for this same period.

Page 15

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE REVENUE CHANGE - TOTAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)



	A		B			C=A+B		D		E		F			G			H=D+E+F+G		I			J=(C-H-I)/H
	BD Reported		Divestiture Adjustments (a)			Comparable		BD Reported		Bard Q1 (b)		Intercompany Adjustment (c)			Divestiture and Other Adjustments (a)			Comparable		FX Impact (d)			FXN % Change
	2019		Divestiture Adjustments (a)			2019		2018		2018		Intercompany Adjustment (c)			Divestiture and Other Adjustments (a)			2018		FX Impact (d)			FXN % Change
BD MEDICAL
Medication Delivery Solutions	$	3,859	$	—		$	3,859	$	3,644	$	213	$	(3	)	$	(9	)	$	3,845	$	(101	)	3.0
Medication Management Solutions	2,629		—			2,629		2,470		—		—			—			2,470		(26		)	7.5
Diabetes Care	1,110		—			1,110		1,105		—		—			—			1,105		(28		)	3.0
Pharmaceutical Systems	1,465		—			1,465		1,397		—		—			—			1,397		(47		)	8.2
TOTAL	$	9,064	$	—		$	9,064	$	8,616	$	213	$	(3	)	$	(9	)	$	8,817	$	(202	)	5.1

BD LIFE SCIENCES
Preanalytical Systems	$	1,558	$	—		$	1,558	$	1,553	$	—	$	—		$	(12	)	$	1,541	$	(52	)	4.5
Diagnostic Systems	1,547		—			1,547		1,536		—		—			—			1,536		(46		)	3.8
Biosciences	1,194		(9		)	1,185		1,241		—		—			(106		)	1,135		(30		)	7.1
TOTAL	$	4,300	$	(9	)	$	4,291	$	4,330	$	—	$	—		$	(118	)	$	4,212	$	(129	)	4.9

BD INTERVENTIONAL
Surgery	$	1,397	$	—		$	1,397	$	1,192	$	153	$	—		$	(18	)	$	1,327	$	(13	)	6.3
Peripheral Intervention	1,389		—			1,389		1,045		334		—			—			1,379		(29		)	2.9
Urology and Critical Care	1,140		—			1,140		800		267		—			—			1,068		(12		)	7.9
TOTAL	$	3,926	$	—		$	3,926	$	3,037	$	755	$	—		$	(18	)	$	3,774	$	(55	)	5.5

TOTAL REVENUES	$	17,290	$	(9	)	$	17,281	$	15,983	$	968	$	(3	)	$	(144	)	$	16,803	$	(386	)	5.1

(a)


(b)	Amounts represent revenues for the quarter ended December 31, 2017. BD reported a Gore royalty amount, which was previously reported as revenues by Bard, as non-operating income in the current-year period.


(c)	Represents the elimination of revenues from the Medication Delivery Solutions unit which BD previously recognized from Bard as third-party revenues and that would be treated as intercompany revenues in the current-year period.

(d)

Under U.S. generally accepted accounting principles and as a result of Argentina’s highly inflationary economy, the functional currency of the Company's operations in Argentina was the U.S. dollar for the twelve months ended September 30, 2019. The total foreign currency translation impact above includes $22 million that was calculated by comparing local currency revenues in Argentina for the twelve months ended September 30, 2019, translated using the prior-period exchange rate, to the reported U.S. dollar revenues for this same period.

Page 16

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)



	Three Months Ended September 30,
	2019			2018			Growth		Foreign Currency Translation		Foreign Currency Neutral Growth		Growth %		Foreign Currency Neutral Growth %
Reported Diluted Earnings (Loss) per Share	$	0.41		$	(0.64	)	$	1.05	$	0.02	$	1.03	164.1	%	160.9	%
Purchase accounting adjustments ($364 million and $374 million pre-tax, respectively) ⁽¹⁾	1.32			1.39					—
Restructuring costs ($81 million and $57 million pre-tax, respectively) ⁽²⁾	0.30			0.21					—
Integration costs ($118 million and $88 million pre-tax, respectively)⁽²⁾	0.43			0.33					—
Transaction gain/loss and product-related matters ($585 million pre-tax) ⁽³⁾	2.13			—					—
Impacts of debt extinguishment ($1 million pre-tax)⁽⁴⁾	0.01			—					—
European regulatory initiative-related costs ($22 million pre-tax) ⁽⁵⁾	0.08			—					—
Net impact of gain on sale of investment and asset impairments ($63 million pre-tax) ⁽⁶⁾	—			0.23					—
Hurricane-related (insurance proceeds) recovery costs ($(14) million and $2 million pre-tax, respectively)	(0.05		)	0.01					—
Transaction costs ($(5) million pre-tax) ⁽²⁾	—			(0.02		)			—
Dilutive Impact⁽⁷⁾	—			(0.07		)			—
Income tax benefit of special items and impact of tax reform ($(359) million and $398 million, respectively) ⁽⁸⁾	(1.31		)	1.48					—
Adjusted Diluted Earnings per Share	$	3.31		$	2.93		$	0.38	$	0.02	$	0.36	13.0	%	12.3	%


(1)	Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt.


(2)	Represents restructuring, integration and transaction costs associated with acquisitions.


(3)	Primarily includes amounts recorded to Other operating expense, net to record product liability reserves, including related legal defense costs, of $582 million.


(4)	Represents the impacts recognized upon the extinguishment of certain long-term senior notes.


(5)	Represents initial costs required to develop processes and systems to comply with emerging regulations such as the European Union Medical Device Regulation ("EUMDR") and General Data Protection Regulation ("GDPR").


(6)	Includes $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit.


(7)	The amount in 2018 represents the exclusion of share equivalents associated with share-based plans from the reported diluted shares outstanding calculation because such equivalents would have been antidilutive due to the net loss incurred during the period. The adjusted diluted average shares outstanding (in thousands) were 274,693.


(8)	The amount in 2018 includes additional tax expense, net, of $365 million relating to new U.S. tax legislation.

Page 17

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)



	Twelve Months Ended September 30,
	2019			2018			Growth		Foreign Currency Translation			Foreign Currency Neutral Growth		Growth %		Foreign Currency Neutral Growth %
Reported Diluted Earnings per Share	$	3.89		$	0.60		$	3.29	$	(0.62	)	$	3.91	548.3	%	651.7	%
Purchase accounting adjustments ($1.499 billion and $1.733 billion pre-tax, respectively) ⁽¹⁾	5.46			6.55					(0.01		)
Restructuring costs ($180 million and $344 million pre-tax, respectively) ⁽²⁾	0.66			1.30					—
Integration costs ($323 million and $344 million pre-tax, respectively) ⁽²⁾	1.18			1.30					(0.01		)
Transaction gain/loss and product-related matters ($646 million pre-tax) ⁽³⁾	2.35			—					—
Impacts of debt extinguishment ($54 million and $16 million pre-tax, respectively) ⁽⁴⁾	0.20			0.06					—
European regulatory initiative-related costs ($51 million pre-tax)⁽⁵⁾	0.19			—					—
Net impact of gain on sale of investment and asset impairments ($30 million and $(151) million pre-tax, respectively) ⁽⁶⁾	0.11			(0.57		)			—
Hurricane-related (insurance proceeds) recovery costs ($(24) million and $17 million pre-tax, respectively)	(0.09		)	0.07					—
Transaction costs ($1 million and $56 million pre-tax, respectively) ⁽²⁾	—			0.21					—
Financing impacts ($49 million pre-tax) ⁽⁷⁾	—			0.19					—
Dilutive Impact ⁽⁸⁾	—			0.30					—
Income tax benefit of special items and impact of tax reform ($(622) million and $265 million, respectively) ⁽⁹⁾	(2.26		)	1.00					—
Adjusted Diluted Earnings per Share	$	11.68		$	11.01		$	0.67	$	(0.64	)	$	1.31	6.1	%	11.9	%


(1)	Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt. The amount in 2018 also included a fair value step-up adjustment of $478 million recorded relative to Bard's inventory on the acquisition date.


(2)	Represents restructuring, integration and transaction costs associated with acquisitions.


(3)	Includes amounts recorded to Other operating expense, net to record product liability reserves, including related legal defense costs, of $914 million and the estimated cumulative costs of a product recall of $75 million. Also includes the pre-tax gain of $336 million recognized in Other operating expense, net related to BD's sale of its Advanced Bioprocessing business.


(4)	Represents the impacts recognized upon the extinguishment of certain long-term senior notes.


(5)	Represents initial costs required to develop processes and systems to comply with emerging regulations such as the EUMDR and GDPR.

(6)

The amount in 2019 represents a charge recorded to write down the carrying value of certain intangible assets in the Surgery unit. The amount in 2018 included the net amount recognized in the period related to BD's sale of its non-controlling interest in Vyaire Medical, partially offset by $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit as well as $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit.


(7)	Represents financing impacts associated with the Bard acquisition.


(8)	Represents the dilutive impact of BD shares issued in May 2017, in anticipation of the Bard acquisition and BD shares issued as consideration transferred to acquire Bard. The adjusted diluted average shares outstanding (in thousands) was 260,758.


(9)	The amount for the twelve months ended September 30, 2018 included additional tax expense, net, of $640 million, relating to new U.S. tax legislation.

Page 18

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY 2020 OUTLOOK RECONCILIATION



	FY2019			FY2020 Outlook
	Revenues			% Change	FX Impact	% Change FXN
BDX Revenue	$	17,290		4.0% to 4.5%	~1.0%	5.0% to 5.5%

				FY2020 Outlook
	Full Year FY2019			Full Year FY2020 Outlook	% Increase
Reported Diluted Earnings per Share	$	3.89
Purchase accounting adjustments ($1.499 billion pre-tax)⁽¹⁾	5.46
Restructuring costs ($180 million pre-tax) ⁽²⁾	0.66
Integration costs ($323 million pre-tax) ⁽²⁾	1.18
Transaction gain/loss and product-related matters ($646 million pre-tax) ⁽³⁾	2.35
Impacts of debt extinguishment ($54 million pre-tax) ⁽⁴⁾	0.20
European regulatory initiative-related costs ($51 million pre-tax) ⁽⁵⁾	0.19
Impact of asset impairment ($30 million pre-tax) ⁽⁶⁾	0.11
Hurricane-related insurance proceeds ($(24) million pre-tax)	(0.09		)
Income tax benefit of special items and impact of tax reform ($(622) million)	(2.26		)
Adjusted Diluted Earnings per Share	$	11.68		$12.50 to 12.65	7.0% to 8.5%

Estimated FX Impact					~2.5%

Adjusted FXN Growth					9.5% to 11.0%

FXN - Foreign Currency Neutral


(1)	Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt.


(2)	Represents restructuring, integration and transaction costs associated with acquisitions.


(3)	Includes amounts recorded to Other operating expense, net to record product liability reserves, including related legal defense costs, of $914 million and the estimated cumulative costs of a product recall of $75 million. Also includes the pre-tax gain of $336 million recognized in Other operating expense, net related to BD's sale of its Advanced Bioprocessing business.


(4)	Represents the impacts recognized upon the extinguishment of certain long-term senior notes.


(5)	Represents initial costs required to develop processes and systems to comply with emerging regulations such as the EUMDR and GDPR.


(6)	Represents a charge recorded to write down the carrying value of certain intangible assets in the Surgery unit.

Page 19

EX-101.SCH 3 bdx-20191105.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 bdx-20191105_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 bdx-20191105_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bdx-20191105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] Depositary shares Depositary shares [Member] Depositary shares [Member] Notes 1.000% due December 15, 2022 Notes 1.000% due December 15, 2022 [Member] Notes 1.000% due December 15, 2022 [Member] Notes 1.900% due December 15, 2026 Notes 1.900% due December 15, 2026 [Member] Notes 1.900% due December 15, 2026 [Member] Notes 1.401% due May 24, 2023 Notes 1.401% due May 24, 2023 [Member] Notes 1.401% due May 24, 2023 [Member] Notes 3.020% due May 24, 2025 Notes 3.020% due May 24, 2025 [Member] Notes 3.020% due May 24, 2025 [Member] Notes 0.174% due June 4, 2021 Notes 0.174% due June 4, 2021 [Member] Notes 0.174% due June 4, 2021 [Member] Notes 0.632% due June 4, 2023 Notes 0.632% due June 4, 2023 [Member] Notes 0.632% due June 4, 2023 [Member] Notes 1.208% due June 4, 2026 Notes 1.208% due June 4, 2026 [Member] Notes 1.208% due June 4, 2026 [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Exchange [Domain] Exchange [Domain] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 7 bdx-20191105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 bda12.jpg begin 644 bda12.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Cover Page Cover Page

Nov. 05, 2019

Entity Information [Line Items]

Document Type 8-K

Document Period End Date Nov. 05, 2019

Entity Registrant Name BECTON, DICKINSON AND COMPANY

Entity Central Index Key 0000010795

Amendment Flag false

Entity Incorporation, State or Country Code NJ

Entity File Number 001-4802

Entity Tax Identification Number 22-0760120

Entity Address, Address Line One 1 Becton Drive,

Entity Address, City or Town Franklin Lakes,

Entity Address, State or Province NJ

Entity Address, Postal Zip Code 07417-1880

City Area Code (201)

Local Phone Number 847-6800

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Entity Emerging Growth Company false

Common Stock | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security Common stock, par value $1.00

Trading Symbol BDX

Security Exchange Name NYSE

Depositary shares | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A

Trading Symbol BDXA

Security Exchange Name NYSE

Notes 1.000% due December 15, 2022 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 1.000% Notes due December 15, 2022

Trading Symbol BDX22A

Security Exchange Name NYSE

Notes 1.900% due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 1.900% Notes due December 15, 2026

Trading Symbol BDX26

Security Exchange Name NYSE

Notes 1.401% due May 24, 2023 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 1.401% Notes due May 24, 2023

Trading Symbol BDX23A

Security Exchange Name NYSE

Notes 3.020% due May 24, 2025 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 3.020% Notes due May 24, 2025

Trading Symbol BDX25

Security Exchange Name NYSE

Notes 0.174% due June 4, 2021 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 0.174% Notes due June 4, 2021

Trading Symbol BDX/21

Security Exchange Name NYSE

Notes 0.632% due June 4, 2023 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 0.632% Notes due June 4, 2023

Trading Symbol BDX/23A

Security Exchange Name NYSE

Notes 1.208% due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security 1.208% Notes due June 4, 2026

Trading Symbol BDX/26A

Security Exchange Name NYSE

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_EntityInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details

Name: dei_PreCommencementIssuerTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details

Name: dei_PreCommencementTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details

Name: dei_SolicitingMaterial

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details

Name: dei_WrittenCommunications

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_EntityListingsExchangeAxis=exch_XNYS

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_DepositarysharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes1.000dueDecember152022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes1.900dueDecember152026Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes1.401dueMay242023Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes3.020dueMay242025Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes0.174dueJune42021Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes0.632dueJune42023Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=bdx_Notes1.208dueJune42026Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 a093020198-k_htm.xml IDEA: XBRL DOCUMENT 0000010795 2019-11-05 2019-11-05 0000010795 bdx:DepositarysharesMember exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes0.632dueJune42023Member exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes3.020dueMay242025Member exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes1.208dueJune42026Member exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes0.174dueJune42021Member exch:XNYS 2019-11-05 2019-11-05 0000010795 us-gaap:CommonStockMember exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes1.401dueMay242023Member exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes1.900dueDecember152026Member exch:XNYS 2019-11-05 2019-11-05 0000010795 bdx:Notes1.000dueDecember152022Member exch:XNYS 2019-11-05 2019-11-05 false 0000010795 8-K 2019-11-05 BECTON, DICKINSON AND COMPANY NJ 001-4802 22-0760120 1 Becton Drive, Franklin Lakes, NJ 07417-1880 (201) 847-6800 false false false false Common stock, par value $1.00 BDX NYSE Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A BDXA NYSE 1.000% Notes due December 15, 2022 BDX22A NYSE 1.900% Notes due December 15, 2026 BDX26 NYSE 1.401% Notes due May 24, 2023 BDX23A NYSE 3.020% Notes due May 24, 2025 BDX25 NYSE 0.174% Notes due June 4, 2021 BDX/21 NYSE 0.632% Notes due June 4, 2023 BDX/23A NYSE 1.208% Notes due June 4, 2026 BDX/26A NYSE false XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 10 97 1 false 10 0 false 0 false false R1.htm 0001000 - Document - Cover Page Cover Page Sheet http://www.bd.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports a093020198-k.htm bdx-20191105.xsd bdx-20191105_cal.xml bdx-20191105_def.xml bdx-20191105_lab.xml bdx-20191105_pre.xml ex99109302019.htm http://xbrl.sec.gov/exch/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a093020198-k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 10, "dts": { "calculationLink": { "local": [ "bdx-20191105_cal.xml" ] }, "definitionLink": { "local": [ "bdx-20191105_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a093020198-k.htm" ] }, "labelLink": { "local": [ "bdx-20191105_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bdx-20191105_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bdx-20191105.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 39, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 8, "memberStandard": 2, "nsprefix": "bdx", "nsuri": "http://www.bd.com/20191105", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a093020198-k.htm", "contextRef": "D2019Q4DateofReport", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page Cover Page", "role": "http://www.bd.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a093020198-k.htm", "contextRef": "D2019Q4DateofReport", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 10, "tag": { "bdx_DepositarysharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Depositary shares [Member]", "label": "Depositary shares [Member]", "terseLabel": "Depositary shares" } } }, "localname": "DepositarysharesMember", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes0.174dueJune42021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 0.174% due June 4, 2021 [Member]", "label": "Notes 0.174% due June 4, 2021 [Member]", "terseLabel": "Notes 0.174% due June 4, 2021" } } }, "localname": "Notes0.174dueJune42021Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes0.632dueJune42023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 0.632% due June 4, 2023 [Member]", "label": "Notes 0.632% due June 4, 2023 [Member]", "terseLabel": "Notes 0.632% due June 4, 2023" } } }, "localname": "Notes0.632dueJune42023Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.000dueDecember152022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.000% due December 15, 2022 [Member]", "label": "Notes 1.000% due December 15, 2022 [Member]", "terseLabel": "Notes 1.000% due December 15, 2022" } } }, "localname": "Notes1.000dueDecember152022Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.208dueJune42026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.208% due June 4, 2026 [Member]", "label": "Notes 1.208% due June 4, 2026 [Member]", "terseLabel": "Notes 1.208% due June 4, 2026" } } }, "localname": "Notes1.208dueJune42026Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.401dueMay242023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.401% due May 24, 2023 [Member]", "label": "Notes 1.401% due May 24, 2023 [Member]", "terseLabel": "Notes 1.401% due May 24, 2023" } } }, "localname": "Notes1.401dueMay242023Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.900dueDecember152026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.900% due December 15, 2026 [Member]", "label": "Notes 1.900% due December 15, 2026 [Member]", "terseLabel": "Notes 1.900% due December 15, 2026" } } }, "localname": "Notes1.900dueDecember152026Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes3.020dueMay242025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 3.020% due May 24, 2025 [Member]", "label": "Notes 3.020% due May 24, 2025 [Member]", "terseLabel": "Notes 3.020% due May 24, 2025" } } }, "localname": "Notes3.020dueMay242025Member", "nsuri": "http://www.bd.com/20191105", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPageCoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0000010795-19-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000010795-19-000043-xbrl.zip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
HE8?F(EG)K/@7/2^%CM'IY^_G$H2N ,P9 @& MBX/AJ/LR',"D5(VZ=,ZTUP/;'6!U7E@MLI8!JY5D=5=O5K_#Y'H&3-X[2S^A M[@Q[TY=Z H,%HAIU"NDJL>QZ6JBO&.8NQRTH 4 P38@$*D;40@$"D%A[]S^ M]F<\&_WY H\CO?D.\15>ST 6?A"1"?!:?UY_^]/>Q8)5>]\G?^"$C/T L_,) MCRD9)& %&LP[[Z%SJ]?O"NV/5'M:TET%M9@*P !@ # &,@M!F0ZRT2R2<@M MXDPD=.[.%48^X#J7E'@U]=\FNA-*[@UGU"4DU/Y'E!N1=QIU> MG\U2JRX28][[C,*^2$#_ =#?$#I\ ] /Z%AJW]4($A+%JBKE\'> M SM1DY+Z&R#K#"4D_S.(X?V''MX2N:$/F$7EU;U&?E 2%>S XHKI49%1-%+ M=Z"F5!"%T[-3 F>M*=2C%, )X-R[6U81.K@)CG97&PZ^)A$)41<'+^WKT83,%#U .<7++)FFB"TMJUK70'NKCRA# M1&4#H@!1:;I4^GA.&B!00=090H8G:#' T$:D4JEL:6XR710P6Z%>"XGVK(B@YPU"W!]<+Q,_E*;+T-/VD.>,MR'XCZAY"V2T9# MJ-Q#Q7/M\AXC!:'50VA;I88I5&0(0@M""T*;T7'?9GL?,BL4/H'COD'*#[!3 M5,BOA34*T"L!>@7+CE5$[_N1FSF%F$LTR79G'5&43+#E;$HHE7;3F'#@/G ? MN)]/PN5L20G.9K#W4#):=:P$>K@7>VSJ^ 42L"_Q^",-\S4 MZU#4K;(S#A(FOX150<) PD#"]E4@5H/&D2"1"F]D,LJP0 .KXX=@AWIA IG0G>T&Q@()9,MMP-(KB MRX"^X*S43 G@%-&$_]!LTE]J$\.4>!+4 MZ','J !4 "JRG@1 !:!"ELH,B2<$)@%0(=I'7HE,Y#O]-/OVR+K\;MFC_L"6 M)ATK:_MH#6C5G3[@I3[T 2_UH2_3EHO 2^#E7BU!U3=##9?!E 3WJKE(JLDQ MM!E+-0$CZVR%ITM]$I!%7Z[H)<7]#OLHKX7D>"6>"P9!>&S MU&D]B./=$JG#E%6W Z*R1Y11$SFE'A %B'JM40OTRE0<@0JBKEHMB^P:!34& M(-H 45VH18_TGHKJ*=*K@(YZ>H^P-T%=^@M^T& 7!R1KKUHRD=.U]YM9,FM" M/0%DBRT ./4#9TNLQPQ $Z"Y_QQ7JCED?7PTG<&L$X!K%3UR"H!'3?!8$XHR M2(='W7)<,O6SE$J\I&E$ OVU=@I,E=H5H=:[*O9? :$%H=5#:(WJ/IJ$@="" MT(+0[BMD4A>IAH"^?B#D:O;UJ[3%JHAAC0+X2@#?JED6.K%,1?CF)MW_<8!K M1?AN;3FTF@K & , 8R"T&1.L5B5 +VF4=Y'_8F4\.51G"\1OG;)^CK_=V,T[+",H^3PD8KQZ>3I M\![QV*S5%JF<3_)\Q,)C:E8>#:G]T1&U=QO0F+">3WN;D]75AX\'']8%GA*4 MC$M WIX D_\["Y*'+.C3CZX#@G\>X1LZXF/LWN'[L+ %M?L1G%']*^.W4/=P?E%Q_XA+C0I#&QX=7%Q9IU;-HNF]NUO@\OS M#CM;9_M!I3"(2ZL[L+O]LSY_-1I\0Y?6Q>!R9/62 "_J_J-C_VZAT2">M7$B_'GS\9X?S+'[R'@QC=@PXXLG&A/777W[M6 4^.=P@K7:-.OM2KW:KG]*#(FQ[[IX$9+CY(]G MY!?6"9J'=%6E\'K^)GYCI?7II/#,YEE]]_I7YNM?-87N>N-=8L,P#:';JH=\ MV4$I$YSAMP;R\)6D^<'61Y54:S?_2"'JX"@J\.@#7H)L C^!OLSQ M"L?]J<=8@.V[:G8?*9P/S,>S,+3@C'0D835H8(#RCC-R*@FK937T-6%S5Q(V MRRS1BK"R]_7T_\K"3EB ]'(!]@!7ZVNQ<]3[_*4GFQ>@.W9A1=VOX=1#EV3A M!Q&9Y)/ANM,'@,XQPP/_;LL6\0=AOEA!9VH6IW-+PLB)E@%!GK8IB['/ZIL$[4!>H \FU +G)*)(!<&I K!'5 ,Z!9%,U;&YJ2- H3 MF@7^N D9^P&.'-\[ID20@&V?B2-8YU:OWQ4Z&TCE24E7T6DP$;+S7R;5IP._ M ?B*\%_:.*W&DR /X2#](/T ?,GJB'28".W#[N=D0D?./![4(ZY#*;E'0]]= MLBLARJG#NP\:]TR12%?"74;]M%.5X+#K%9'^O=O.I9J-TE8!P?C">W%IF58^ M$'T0_0^(OBG28%%OT==+M@'W+RN@5L5\VJX*L _8SP'V0>>#N9=?XIM Q":^1*.O2MV=P*KLF M@M J*;0UH;,>0&CE<>#T!*9XK # "> $K:D ,,'4D=34T4A0RPT=!%6OPHN> M@Z])1$+4Q8$L^YME=BAD%"RS;BH4B8-P-@B4[ )5$]GVJ[= J>&YR(@FR+0# MHD _P8*O]X*OGA"515)DTGN=:L=#+F8XF.,Q67+*T/ ^C,@6:%4A; MYW@I!*%54FB%.JZ T*KH#2D%3$A; SBE!2=H33!U-#9U]!'46EF+^A*]TM:C MP4BH"YH2Q.TJ77OHY"C6HC2[36;;SD'J)*=E'92J#:%JF7?H3H6/D"" ! 'H M+-!9SW561JD7>.UCOK?[/0L-NW[*XUS&\X9NN50_=PN02Z7WWR M P#?W 71]V MWC=QR&*2]YB;X:Z5BB%RHIUTNU94CMSE)EH'>@?TSKI K:U%DU>IY$LFQ0*R M!?T,0+Y OG24+UB[P&;.J\VL5$N&2ED+YU:GY#H_26#J^2$=_@[Q,B4HU;W[ M>0-.Q]5F40.!DD"@ZM"N6RH/3&DTP7$"@"C03[#@Z[W@JR=$99%^GM*[GFH' M14X=/QP[Q!L3*-Z09:O#W@6QID5P"**X$@0R06@/=O!''80V)RZ04L LIIH2 M?,ZR74A,1^5\!ASG ,>F*>+C@X(%JT@)JT@C06V4M9!4O9+;<-[ &]"3IDKF9%_&5L_ )FKYF.PG0+EDB5$"[9(6 M I(#J !4 "H %8JA E99A8 "AQ)\S(>;TP&Y1(5@Q#N'$O3MD77YW;)'_8$M M30$*M(I6.;8&H46 ,O 2> F\!%["$J,=>^$D@J=>@-I['X;+8$J">Z2:=ZR: M&$,3U91Z,S:UV+ZBR,UUN8 $UPW @2@Y$@7Z"Q5XF85).@*KEJD(" ME),ZC:N CGEZC[ W05WZ T8?ZN* 9!T;D4S:]&RO*^; 2A<@@BBN!,%,$-@# M"*S9@K.> 9@2 A/R[0!.:<$)6A/,'$T%5B,A-87B ]))J5[9:IE.$)!*M*1I MI@?M/T5I;K2%%(Z*_0,A'0#:"K25VMJJMH]>Y#G65B"N(*Y2!L1 9$%D061A MA55>7,$?D)0^>;15:CM=:GD1W9P4)GTPCH0D06=!3I+ YU5JPDU70*=I9!3#0*KC< 6 M]Y'S?0YBR3G_&:0;I%M#Z6;+,;@0X$* "Z%H84>M+-1G6$7QY:'*+Q&^=LGZ M.O]W8S3LB,VCY,#2BO'IY.GP'C&XUEK\M3L+G@^7CQ&-B>NN7O>U8!3XYW"! MQ\GG%UXQWI>TSK M8^FHQ2_]L$&)/V1,T3&>O#/(U)5,9^XOO2A$CC=VEQ."\.1?RS":$W;MQ@_0 M:>]O(:(C(F'D1,N (/\&.?2[SN06>V,R0:>.OPC\,0E#.EWH>DG_0_\NO]3# M]A&JI4,R_X=???BXY2#'A'7O34,?7. I64_=A^\VG[:EX__.@N0A"_KTH^N MX)]'^(:.^!B[=_@^+&Q![7YTW2L3+P!_X5&=6MW1P$:]?O>/OCVD?W7L'NH. MSB\Z]H]G #GDP(97%Q=GUKEELSQ/W_XVN#SOL$.4MQ]4"H.XM+H#N]L_Z_-7 MH\$W=&E=#"Y9SNG2^F[95Q;J_J-C_VZAT2">MMB$'DS^]K78.>H=69^_], 5U("Z/*VV MISUT219^$)&))$S5W>G+MR<@5J$-:-\#&@+_3J9E.EMD]#:JHCL;9=,?K/K6 M$RD'H#5;[G?]^0('K$Q1$F:#W;9'NTTRQ;=__^3/>&;Z%.3C"!6O95%IF7FE M^4. C3ZA[@Q[TYA,!R*4! M.4!=/:B#X7+(#A@*T?C_V_O:YL219-W/]_Z*"N_T+AV#&=[!W6_&XI/P>P?E&2%U#I,W>Y9(YM3D75J=U;FI;9GISTW[L@ G%YM #="_ ML/1OR=3#-IO^9BU O??-T#=>JTNHP-@']C7&_NP^0CY$/(5EOZEF@S]7^,E M?P6HDG9NK)O,"''M2E4CAU.(U)IG\X[GEF?=<[$_[6GFL: S[NK-N^^;G+7V MR[H@.^E:U3!QS^#4.GX$<;4D;E.JXAF(JTXD9R8PY>?6 $Z $U93 V BW$&X M<^AI*ZGZZ^])J/MTELD.R!SLUFH5F3E7Y;R.69EW?<>ZY1$/6<\*##^G)[<: M"OL/YV1FKU2-VA"<@50JD*K1 JE4BH2T1A-2K8 HV"LI/?>@]NWPYM8*99?,XD8Q=+\*(SY ,5)1)]D:U;L(\)5;'L#I6 M+.+6NS)#(A!7H0#.3& B&0C@5!:8B9[5F6JYVI#;ZO2-W M)GK$DBN67&&W8+>^;[?J4H-TV"T-PW@05GO"[C#A"\J"LJ L?*P!A,780'$9 M8;?TMUNEAM2NR@VEWFHQ($_5(^%597IGA/5.1>:6I;^_0 ME;DBO2"=H&:]HX*B8JOPMJ!]I$PG@#E !5 !5 5FJ$"7E8CH( Y0(4JZ;>J M=HA)*8/)[2;<]H/D$/U/I#D>N(['Z59G??9U^&7 KGO#P:@WN%9D@D[E*L6F M3TB:LZP$, /,^LL'79HC'W0))P,G S K)]]>#P13258UEVRS/QTIX)9GN0L< MCG3@[+*=-S\>,JOJ/>7F>7+FB1%;3W6:EU>-?K ]L#TYV9X.;(_&,1ZXI2ZW M<,H6^ 5^P7>IS2W$S8B;87NVE:>4J>EYC;Q=1,119WIG3NW=;U:,J+9K4MY2 M4O?PWO-#:OX.4]A:2&IXR99Z4\8UJ!I$L8$J50@55UF4[G9I#)W$5W=B3D@ M"HB"?8+3A]-7=8[%E*D4 RRZ=H"K-2HRE=:4GP#1>Y;\S/%#V^&>S9'5I\I> MQOTO[:'D8<$C,!!71^+6JS+U@T%:9&W*, - U@W(M2YV"R T M0FBD'7%+F98UA0-2WP&9@]U.Q8A46[-2AE =\0WH*7/4>([YLYI7$F@WI"8! M=3Q='2NRL%JP6F98K;I4J 2KI6$(#[IJ3U?)>6&4*P*]06_UZ=VN[J,:68&] M,<80BLL(JZ6_U2K5I'9H(BA!4'(X>J.&HAD)NZA&DF\GH$:-0JA =2>-@ +F M !5 !5 !5&B&"GA9C8 "Y@ 5JN3HJMHA[X_L9]0@E^LP _U.#<7A:#RX^OM@ M-!Y>C)1)/T1MJWRLG0+A@/[B \K0)70)74*7<#$FJA=0-D<^%$]\.:+3>S/N M=1S<\V#!=)OIT(W&J+N04;8(CIW/P:=;N(B%/.]+9!^\9NK5$QXFQ-D[*1COYZ M29_.Z2O+94,OXL$W[HF$)DI:P/8IG5%EUH+99*,"2]!IIS)U)39.&LVF8 F MU$0$HM1 %.P3G#W(E-6TBDS@;,KLB0'@TPYP;:D3WY6?\= [6^\FH#;?+YCE M35B/+A#RL9X5\+QGYA1CFYD%1$ZJ)DQ.8C5/@9ET\/4 ?.UF6O"GH'P%+A6: MZ@$X 4X83?5QB2 '?#W4Q%0-^3[%PK$YV&W+'3VLFK,Q*]U'I:J&2C%+F8._ M<:Z_K,R-O9SKK^19YUA/A;6"M=+;6E51?Q5T!5TUH>L.T[J@+"@+RL+#:D]7 MC <4E0_62G]K5=I'H3:I&7\4)02[][L*+;<16$?'7)#4V>VQ;9#8NYW.:U!' MJ*=_%>IIJ]_636I?7[1J=*E>_+P:AI,I^%V6I9F>OE:AVK:_FMKJG&:=@MV"T=[%:M M?")U2B+LEIJS22"LX80MU?>Q5HAU<=!;.1T7D=[DCQM2>USACS&.P#@"=BNO ML*0M=5P8PA*$)8>C=U9582N%V5>;+$G\$EFW+G_\//F[UAK7\?CQE*?NM5[] M\#ES5KUN7-(B9G/778+CUZ/J4?(^G%OVZOUW'C%V9CQD(_[ KOR9Y7UFKWOB M^0K,@S.)II^:W91B2TUOO&!#VCQZN[.>R_J<"\WTH5O;8FLK,T1M_/Q.(S/7 MZ.G,C[TH9(YGN_&$,VORKSB,9EQ\=N<'[*S_EY!1BW@8.5$<<.;?,8>^.YU\ MLSR;3]B9X\\#W^9A2-W%;F/ZAUY7WH,P>Z)* MC[M@EFWS>42@H!<"5@(1\X"@YSDEV, MG<\AFU*CZ5:.=^=:HMZ/%2P8MWW/GRW*+)IR=A=[=O*%R^PX"+AG+\2=Q%<] M?S:WO 4AUI]3D\15 ME/3V$/]'QQ9=+PB>^Z5I# 7'SVG]@*(A**DV@3=BTD MF=W2^T:US.K5VDF%I9YW3-=&?D3/IU]2'WM/[8@"RPO3=C.'VF)'S+JE$&!% MK_"Q>M'6H6R3T? M[]B ?^->S%_TXJ8]5G[L$/HZ3@R$^!E!P@^.24../V'\#WMJ>?>7 M%G7T]@!:_KKV9T]V/;P-N_?O8NJ,6?[+GHS[K79Q?GH[^^0H@AVS8]_#=CX(NVUJ].SKX.77QZS[YP>=>#^'$\#SMDY?3P-V>"U091F76*W2^0! MR?3&?/(Q5RE+-YX53QRRS)_94^BX M\X.9Y3X;O-:J:2"66=3YHK5IC-EN5%JM;JW:KK5/ZB?MDY,/J[&D+1S8/.2? M5B]>B?\4MCXEW[6/?ARFID^L-SZL!;4OOOOQ5[4??]61^M4;SY)KQDG6S5#D M65TUNC?S9FS6AV;E519]*>']_/ ]SCMNT1^OPF?9J1)%5*W2E#*@K"64SQ11 MM7([_,Q2U=U_]>SGPU7M]G2 I=ZT28H>0OOY9.C_O' M@X^_](W?@@<#MJ$!TP2[9WUVM5RA4D2II@\*BSU2D$M) MKW@(; ?U#)3>>+ MC/Y:8M#I6N80VS+SR4RH'$#6?-6?Y-L$8DU-$64C<-MCX*:8Y=O_ .4?:<\, MTT2N+9/R],/!^\/2XB%@Q#ZP7I*?AC&J =(AY-^PNT3VIB)0,'UDJ]A)A\4" MN]L=V6A I^" VAWL&\3676S 'C4*H/MB7(P1I^[#DFR8->^&Z=G=$@ 7PNI1PGZ _Z;T__=L<$^F,!$KC?T@!UZ[6ZC Z ?6!?;^P;8O,1 M\B'D _TESE"MR513>HV7_!6@2MJYL6XR(\0U*FV-'$XA4FN>S3N>6YYUS\4& MM:>9QX+.N&=S#D&6';%OLIX5;'5,CTY"9N@M5"1672J:4S5H0VP&4JE JF[+!%*9L^"G M-9J0:05$P3[!Z5>JO%@#Q5CX17E>F= M$=9;%:FE:AT]],;%XW-=[IKRU+=WZ,I<##J#:Z+.P>_L54T=D+2N&4E@+FX8#9'/NC2'/F@2S@9 M.!ECP&R.?'L]$$PE68MR.E+ +<]R%S@_'C(K*KWE)OGF6LG./# MC )!Q[ ]L#VJ&1[5)C(URU>![=RWW0%?H%?X%?!?1?BYKS[1E'A87MRMSTE MJ6-;<-29H6& 5D>=U2HG)OA-D_*6DKJ']YX?4O-WF,+60E+#2[8TJS+L4C7X M1(P)4BE JD979E.YX M;D4G*UZ0]+XSQP]MAWLV1U*?*EL9]QY.->HFS%!B90\K>T4C;LUHXA9@G1VS M4H90'?$-Z"ESU'B.^;.:5Q*HE6M[J26@Y/GJ6).%W8+=,L5N5:6*21MEMPJR MC@W"ZD]8RE=*U<[^R"X7OX8XPB,(V"W=+);I1K"$H0EBM,[ M(ZRWY?8DZ^BA44E1FP5"5*HI)BI0XTDCH( Y0 50 50 %9JA EY6(Z" .4"% M*JFZJG:(2>F%[U12'([&@ZN_#T;CX<5HNR1$;?"SN["IM34)M3E]K3!9L#;H%;J)0(?H%?\%U:IV$1'GG>EM@_:-W2XJ)*HW27U)G\[I*\ME0R_BP3?NB9LII5D3D0UY3) M$P/ IQW@FA69*IS*SWCHG:]W$U";[Q?,\B:L1Q<(^5C/"GC>$W.*L: L!H1MI0I7TV9 MM#(9Q^9@]P09/^I-P5YI;:]. MI+(X8*U 5] U![KN,+,+RH*RH"P\K/9TQ7A 4?E@K?2W5J5]&"NI.7_4)@2[ M]PKUCE0*K):.&;4)M5G:0^V78J("59,T @J8 U0 %4 %4*$9*N!E-0(*F -4 MJ))DJVJ'&)@9R*X&?Q^,;@;7VY! )RE391HP$8=I=NGM]^565^;(!RUG'P]# MVJU".V4X#;L%NZ65W6I6I0X -LIN8<4/A-6$L*6ZU 8H+.B#WJ"W^O1NEAL= M;#?". +C"-@MG>Q6J5U%6(*P1&UZ9X3U=J4P(^9D->*7R+IU^>/GR=^UUKB. MQX]7RR/UZH?/F;/J=>.2%C&;N^X2'+\>58^2]^'N.U&M+FT=N=]5S6YUQHI@_=VA9;6YDA M:N/G=QJ9N49/9W[L12%S/-N-)YQ9DW_%833CXK,[/V!G_;^$C%K$P\B)XH S M_XXY]-WIY)OEV7S"SAQ_'O@V#T/J+G8;TS_TNO*](C//, S@O 6<6^6!<^.1 MD60WE>L*N^>>*#+D+IAEVWP>$2KHA<"5@,0\(&PY4)D[?M>@?%O P=B.! MI=/@7E0E\JQD_V7G<\BFU&BZE>/=N98H5V0%"\9MW_-GBS*+IIS=Q9Z=?.$R M.PX"[MD+<2?Q5<^?S2UO09#UY]0D<96 ]M-3V ,]7UR9-'SBNZX5)#@7G_TG MMH*(A.(DVH1="TEFM_2^42VS>K5V4F&IZQW3M9$?T?/IE]3'WE,[HL#RPK3= MS*&VV!&S;BD&6/$K?.3%UK%LD]'W+MU8]@Y__E.C_CF:6E'2"80>.Z:6DJ2W M"V:+C@N$NES?7N_8@'_C7LQ?].*F/59^[!#Z.DXLA/@90<(/CDE#CC]A_ ][ M:GGWG)&^./W 3RX)^-P/Q*_6%?78F/3Y3LA":T:W2VY4><_B)!\G#FSE.#>F MC,U%_:PLW/NE19)NK\'EKU\=@)+\G0:KF\SI[L>W ;?^?6S=48L_6>Z#M0B/ M-I!V/Z'+4T\_ZW@),R7=JK-!;WPQ8OUA[V_#T36].AWU6>_B_/)T],_GK3UP MPZYO+B^_#LX'(Y&9,1Q]N;@Z/QT/+T:;-RJ#1EP->A>CWO#K,'DTN_C"K@:7 M%U?C07^5+,)ZOY^.?ANP\47::U>G9U\'+[\\9C>CH?C1]?AT_#*_Y,#].G[@ M+EG<<_I\&K+!:],D3;_$@N8J6^G&L^*)0X;Q,WL*W5:>(?R89>/6?OTLJ*E2 M3)/\VJ&N]=+WZ[?W_&!FN<\&C[5J&@=E%O2]:&T:XIU4*[5JM=FH-LE+M[O= M]H?56,X6_F,>\D^K%Z_$?XH:GW(CNT<_CA+3)XJ./'H5G2V_^_%7M1]_U93Z ME=Q7;4.?]<97+4-%-O59A]179Z-?;;SA4Z,% T7F2G-8#MD\$7X/K M 8CL=(\BJL[K^.B"J/D,:BZ"FGN_GOY<4%7#.9D'YSY47115#Q11-1S47M7\ M!6HN@II_4T3-,-Q[5_7OO_9_'OS\Y6?#56ZV=-EL C<#T,-?2[WCWS_^\OLN MA[MII'L@NRBF^JS/KI99%(HH/<0-5_M)TER@5B)+Z:R39LE& M&DQD&B"=1O%^O@00V\P4@0)LOLG#6L"\(# _J+\"R)^#7*9(GD8@ !3T@X+I M]LYT^4!E4!E0WPO4U:Q^F7$O)+>;<-M/#Y3Y%(N3;\2&]W3M\7S0'_9.OZI> M5T9I*VA 1ZBN?V4'[P9W0F$%A_:+K'UU!(?3@].#V2LJ^Z'](FL?MK_8ME_1 M91QCNT =L6'R5-PN:D!'&)]9=F#HGK(K(8C4J74\R)1(?:= M/%N./;<\ZYXG)UWMLB"K=W^HFHZP?Q]7JS:SU+:JSL_D-"$SH2F_<@EP IRP MFUI 4]O1!,(='6E;*Y^T.J M/(IZT$2X W "G 4#)QP[ %I$@!8)FH@Y,534 MGK!J"+]OJG8J,NN]RA'5K)V#?<>ZY1$/6<\*5*G!H'+!L.7P%"M6561\TF%,PS'#X0!43I@RAX/:!*&U09 MB"=$41B6J&:@M2-136I27_FY>[U7E2ZG5C"S;!XGDK'K11CQ&;:=%&5-O"%U M-(MR"VU*@5/5X9]6P$0>$<"I+#AA-0L]@$"HHR5ID?P';Z(B,!'J )P 9\' M";<.@!81H$6")B).#!,UIZL:PN^;J"<5(XAJUG:3\<7X]"N6=[\/O=0F+B5X M;11E^F!Y3W'%>U96B8-)-^V#S$7.*J>D7*NU]R!W)GK4,R5%X5@ A-6>L#N, M-$%94!:4A8\U@+#:#L7*O(&NH"OHF@-= MI:K3;2KT5B6Y\M2\X?6ZP/ B,URFJ!X8KA?#P>U"-[GTAS/' =C].MSOKLZ_#+@%WWAH-1;W!=W&6>C3W'(6">I\$S M0#[HTASYH$MD$\#- ,X*R@==FB,?= D["WVJF#,,32( U S(N17:4@G.:J97 M9E^A)^"69[D+%.@Y<#VLG<_W.^2VCO>4F^/IBIV.5,:W:J#C-$JE@<-83?-U$;<@=/J494 MDS8.'?VU[UCWGA]2\W?(;-!"TIP3=_;-KG9')B!5U=L9,#VB-9KDIQ" *" * M]LGPH!L.7P5"=4$HF&J=*IJ:W)*@5/50:)6P"QENE:L MBZF55CK^N&?9"YR%E9G?))0VK.^1VY,]&CG@DQ"@<#(*SV MA)5;ZMQ0Z*T&IWEJ7F;D"G:#W:JSF]QQ728Y#N[8O*$[AA"P69K8K-H^@I(" MVRQUC1((JS]A=UAZ!65!65 6E#60L@B-0=O,)^M:^YA;QVR=6A0'N0M)[EJY MVY8ZUAD>&7-U"$CR)W"C(K5Q0T?ZJKDI_26#ISPE?H>NS'7$7)!.V+B4>E$Z M!)T 5 50(7JJ-@I3BY('RG3"6 .4 %4 !5 !5 !5 50(6!J$!$KA%0\MGI MK6J'O#\W/*,&N5R'18[D=A-N^X$5.;[WB33' ]?Q.-WJK,^&H_'@ZN^#T7AX M,5)F6V=>Q\F\YS8,D-5T^:!+<^2#+I%*8(AZ 65SY(,NS9$/NC1'/NC2'/F@ M2X1^AJAWK^6]5))UXUDSO4_@NXZ#>QXL=)M,UHW%.Y_B=\A]&^\I-L]#%,O5 M$ZGS4U0[11'L KN48Q?.; >_P"]X+]79I>T $%8'5N?@5N>DB0H!X!:XM9]# M_5$;#MP"MS :!;_ +[WX5:IEZKM>PVX7&0M2 U7,T.HXX:9H0):':UJ MN+4K51-(:M*.H*._7M*G<_K*O1!4(^UK,"GO?2 MDF)LR^>(N[W[M!,92BJWO@9@F@9,Y"("G,J"$U:ST&,'$%8WPK::,DL?("R MN>]5E X\"8"I(# 1?P.< "? "7!N/3BLUP!,# Y-)*PY)*U5*T;L_C)K8\GX M8ES4(C)OPRXUALO6O[:&,O(O[RFN>,^\JK&9=,,^R%SDC"Q.O=R6RA]Y3^Y, M]*AG\@D("\(J.<@$94%94!8^U@#":CL.A[V"O5+?7E6[4@O3L%<@+ A[>,(V M.U+'T8"NH"OHBB$\* O*@K+[."-U0ZFW.BHU3]7+G*,*>H/>JM.[7FXU3N"/ M,4,'>W5 >Y75+@JYG!D=J5N0S=_;8]L@L784=^X>+S)G5!8 MP:%]9'[#)\(G*L<+6,6\.Z&P@D/[L/VP_<44&YI'-%Q41NRV>=F@CI":(=WC M-/]^=AZRF]%P/.BSZ_'I>'"MR(I&#M#69%4#J["R,I^4.PTD,F(9$H35A+"E M?>P2> UBQ36/I"BPVT1VDSNN%R:S DE1&$+ 9FEOL[KE3ENF !QL%H(,$#8' MPK9KV&D,NH*NFM"UU,"('R-^L-M0=G>PRQ'T!KT-I?=)N5%%M(T)/4SH'=IF M977.3V4?_EE)^B9Y/+]$UJW+'S]/_JZUQG4\?CSE*??JU0^?#]*\I$W,YJZ[ MA,>O1]6CY'TXM^S5^^\\8^S,>,A&_(%=^3/+^\Q>/^QYXM*#,XFFGYK=E&A+ M76^[<83NL_D M7W$8S?CJ7F?]OX2,I.%AY$1QP)E_QQSZ[G3RS?)LNNF9X\\#W^9A2%W-;F/Z MAUY7&)-N59=9;NAOW*)PU:30OXM8Y(1A3&#VJ:D>YQ,"]BVU,%PP:N4DMB,F M])'(?68%DQ\(%\Z=P"(KW6E^?O8[$NN4,!4YOF>Y[J+,SOF$E"_>LSYWZ4[! M@EW[;BP^"9.G7 ;Z3J^\!_B*;EI!NENK7+IA9==,NYMP0;744/#OB=RTGQ=*.0K\LHI%@" MO"=:Y2WH6M'H<%WJQYYX(;Y%_]-U E,"-LF#$DDJ[SD-V.FW[/2M\G;Z=&D- M SXGH!(F5II_ NQ_8BN("#,I5/O<7B*UEB"U0Z@[ZXO?^T&46('?A)T+_(7E M$BE2:UMF#U/'GK(' AH]YYOCQZ&[6/M1^/38VT5B!!M5QA[3K0$)B'X&2YM_]ZCQT[26PD\"CA&4R>8')/)CQ9/#Q-V-9I:="<_ M=B=DLEE$[G6):LK^?CGX; ML/%%VFM7IV=?!R^_/"8!QH.K47*7E\6P#MROXS1,/4_#U,'K,%6:?DF$7K+I M8X>LX>1CKF*6;CPKIM$3GWQFJUB(S/-R$!)FVKBU7S]SV%7RU\FO'>IE+WV_ M?GO/#V:6^VS>K%9-?7QF -9>OVKEU3R FHN@YB^*J!F&>^^J_NW7_L^#GPU7N-G2 M BT1]W0MZ7?+#&PSD7( 6?/5?F^9W^OR8BK;=/D4 M"\3S!3N<(-"PA@:1\OH_-;9E"KN9:$!(M$%(A)@(,9%!XU^SI=/4\NU_D>4? M:<\,">1VQ+;<$J,?#MZ?NRP> D;L ^M-+>_^>Q8.$YFZ28>0?\/N$KNY%8$" MYCDPL@7,M8>Y8K7JB@5RF0.Z-0(!H* ?%&#O /6"0!U#M4.>0:B1C+O,*>A< M332YW40<296+CV>#_K#WLLC#S8[>%'C3LG6PAO0$:KK7]F! M^T$*46_BUE6*\0 -PSM!'<$+:@_A#XNM?QB](AL]:+^XS%=T;M_8+H#89HH- MV!=;_[ON'C6S"\Q*LWKS&&JSI[L/.J6_9XEDJIGMTNJ,ZAG5RMU:3:+IF_:F MGC7%U!W" ?E9(?_/?^K6:W49'0#[P+[>V(?5?V,A:[-*DB:$1 C[BFL .JTZ M# !<7^&0WY9) @3L 7N]88_1#K!?5.S3:*>.T0Y&.QCM%-0 E&I5&?Z_!DS^ M&E#ER EC/65&D&M5JAIYG$)L,GFVU'IN>=8]%X=3[;38JG=_;)%DJQHF%2/M9@>%E-S)Q%RH2J]5 5JI2-EMK-"'7$XB"?=HWFK0>/,+I*T"J)I*28:+A M]($H( J(*@*BX/$01B*,S'Q%89>R)KHO'!A@TK5#7+,BLX:E_&R_W@NJEU,K MF%DVCQ/)V/4BC/@,6UJ*LJY<*U<[2 G1W!.8"4TDT@&2NJ5F!UM;BN6#S %O1VI-2SFO M8];6EO'%^/2K(HO"ROG(U,$O)7CMX67Z8(M*[DH<+;II'V0NI$U 6E 5EX6,-(*S6=BMG.Q6J5Z5 M*;6^J=A;Y.O<.79DKT@O2"8^Y MG8U#YG8JW"'H!* "J J5$?%5F/A@O:1,IT Y@ 50 50 50 %4"%]JA [*41 M4, )](<#US'XW2KLS[[.OPR8->]X6#4 M&UPKLL23YY[^]ZRBZ4M:!L@'79HC'W1I7,:0(D"&D]$=S#!,T"5T"5U"EP@8 M$# S&K+M]P)N>9:[0,&> V\"V?G4OD-N?GA/N7F>F=AM MFG!FHE+\TMUG@ENY[T\&O\ O\ N^2[6\'=5"1\3-L#WYV)X3J?W L#WPZ^ 6 MXF;P"_P"O\ O\,M ?B$VQ+@4XU+8GCQL3ZF5J>UY#;U=9,SO#*K"Q@%:%7!K M5:3.AE3-<9JT<>CHKWW'NO?\D)J_0WZ#%I)F6/13179U.S+L4C7Z-,!P:XTF M^4D$( J(@GTJP" 83E\!4K5D2IJ832J8:#A]( J( J),1!0\'L)(A)%9+RM( MU;$T9?7 ).N'>(ZE89&9KP@VQW/'#^T'>[9')L<53D^;^]$K)Z8L"BG%#A5 MC>>U F8IT\5B4V(5X%@W''>JV,96\"$N(B,MB=N6&12#N/ HRDZJ YP Y[[# M]G8'<3N K#^0VR>8&$'&!]/5 YH"W5:F9X'7,VB,SOAB? M?E5D85DY'YDZ^*4$KSV\3!\L[RFN.'C((+5C=,,^R%SDC(Q.O=QHRV15O2=W M)GK4,R5+87<(PFI/6+FUT0V%WBK0S5/SR/4"NTUDMW#',MEQ<,=F3D-A& &[ MI8?=:M:DELQAMQ!H@+"')^P.B02@+"@+RN8P\I=+K\#0'_0&O=6G-PW]6U*K MU_#'&/ICZ ^[E5=84JM+9CHZ.+5G/C^TMT3WGJW#MT M9:Y(+T@G;%RRO"@=@DX *H *H$)U5&PU%BYH'RG3"6 .4 %4 !5 !5 !5&B/ M"L1>&@$%S $J5-DOK6J'O#\W/*,&N5R'1IWR\9Q(-D-5T^:!+<^2#+O-+%S)/?$ 9NH0N MH4OHTE#YH$N$"X:H%U V1[Z]EL]22=:-9\WT/GSR.@[N>;#0;3)9-Q;O?/#? M(?@%JBUG](PJ P#*H**"E"Q?F)$H1N,6C%JA!-\W>#L5(Z9<3-HU=/372_IT3E]9+AMZ$0^^<4_L'V)(XLE"],4&/GYH9]D+G(665AENM-*9/SCMR9Z%'/)"D0%H15@*^@*NAZ>KG+'J6XH]%:K M5'EJ'MNHP&X3V4UC_0;<,<;ZL%>P5SK8JU)K']8*X0CHK1[66Q6IS# =/7-! M]I-OCVV#Q-ZMRK=!'9%W4J!B1GWC"N\F=T)A!8?V<[;]6PU7%;"(!CD">$38 M1-A$:!_,+YKEA^85U#PB(41">7=$0?4ON^'7["YX?U9TCU/[^]F6R(:C\>!J M=#H>7HR4V:28@U'39"4#"Y72E?S*K;;4^44Z+M]@Z1&$U9VP)206(+$ [#:4 MW>2.]Y(Y5&!WK,)TB5*YCJK)"+ME@MVJUV"W$&B L)H0MH'-R* KZ*H+74N= M?4S28=@/>BNGXR+2NU-NGLA4A*%>5!7(*XY'#\SFR? M8V%<=)+1\TMDW;K\\?/D[UIK7,?CQU.>^M=Z]LNX?'K4?4H M>1_.+7OU_CO/&#LS'K(1?V!7_LSR/K/7#WN>PO3@3*+IIV8W)=E2UQMG/)$^ MC][NKN?P>LZ&9OK0K1V6=733FS9G[L12%I(& 1O8\>N/N- MLQE=.@T9]R9\PJ[Y/.*S6QZP1K7,ZM7:25+=F%YTF>/9;CRA^TS^%8?1C*_N M==;_2\A(&AY&3A0'G/EWS*'O3B??+,^FFYXY_CSP;1Z&U-7L-J9_Z'6%,>E6 M=9GEAO[&+0I730K]NXA%3AC&!&:?FNIQ/B%@WU(+PP6C5DYB.V)"'XG<9U8P M^8%PX=P)+++2G>;G9[^KO,=K4.DM*MTJ3Z73)6 #/B=D$>;HU3?NQ?P)P_^) MK2 BM*;H[7-["=Y: MX.(+(31&SE(7)#>@_83>6ZPNZYQP/+=1?,LFUAQB;B MA4"0L(7S@$R8,W=):<+<6/0/H2F,W4C8F=. ?DW76U:P8-SV/7^V*"?(NXL]._G"978/YM;WH+,F3^G)HFK M0KK3TU/8 SU?7)DT?.*[KA5LZ2PJ+(U;A6&/_(A:0;^GGO:>6A,%EA>FK6<. MM8C,IG5+ ?3*F(=LI=VM1X+U.J,+7+JS["W^_*=&_7,TM:*D+PA$=DQ-)5%O M%^0OJ+6!T)KKV^O]^TC_9YVY7<>5'_N%OHX3/RE^3/CP@V-2E^-/&/_#GEK> M/6>D/$X_\)-+R SY@?C5NM9>6"2'/)\UH]LE-WK7_.0>;29_DD^?WF[8*)NZ MGP=9-.O2HJ[>'DC+7[]:ED_^3H/53>9T]^/;@%O_/K;NJ,6?+/?!6H1'&TB[ MG_''#SK^D$ X&_3&%R/6'_;^-AQ=TZO349_U+LXO3T?_? 600S;L^N;R\NO@ M?#!*MRA\N;@Z3[8H;-ZH#!IQ->A=C'K#K\/DT>SB"[L:7%YO'WP>AF MP'J_GXY^&[#Q1=IK5Z=G7P#^'*IE+WV_ M?GO/#V:6^VP2J%9- [/,HM 7K4UCSI-FI7U2:S5:M5:UW6RUZQ]6C7=D9[444;5RIZF8I>8S MJ+D(:N[]>OIS054-YV0>G/N*J!I6:Z]J'D#-15#S%ZBY"&K^31$UPS_O7=6_ M_]K_>?#SEY\-5[G9T@'03S\8FJUJV?/TS%+R?_]:ZAW_?CS\^,OOQI^N!P.V MH0'3!+MG?7:U3/Q11*DY1M.!_Z"2X9+;6I#97,E:KO+I6E[TEDGJ9B+E ++F MJ_TDR3,0B1O%5+;I\BD6B.<+=CA!H&$-#58P8?]38UMN(3$3#0B)UD?SXC9V MNOUA+29B6^XD 5*,1\IZ\"PVY%Q$=-VS,!IQ-.)H@^9,S)9.4QNX_Q78?Z0] M,TSWWY5>[I,P#0?OSW<7#P$C]H'UDOV$NQ3*&W25VVRIB[3 W MAMD0P%Q[F"M6!+18(.^:#0) 03\HF&[O3)TFW/;3 \0^Q>*D,W&>2+HXUH%-0IGQW^W90L96=F#"X$PHK M.+1?!-M?4+'A\F#T8/2@?6@?MA^VOUCZA^:A^4*)#=@76_^RV^;-[@*S<@7/ M^81:GE2GZ'/7(4D6[-IWXZ1<1G%3"#-?M]FS1#)5(7=I=5;EXF/?&*N?:/?@KRX[8^[1:N5V7&3K]4$CE(L4"))";"4WYA7Z $^"$W<1#UK."K6J& MZ21DANY"16+5RK6:3DD-!4B+T1I/V-,,1,%"[=_K:3V A.-7@E95(_+G8::5 MP!,%5-(4F0AZ $^ $. %.@!/@- :<&"SFW3>Y"V\F M=4O-3(EKRO*IR3[('/!V*W43O(Y9._K&%^/3K\7-F7D;>JF#7TKPVL/+],'R MGN**@X<,,L=^;]H'F8NZY79-ZH0LH^P6 @T05A/"RM51!EU!5] U![I* ME7_>5.BMUJSRU#SV X+=1K);JH00V UV@]WJL[M;[M:DQ6J5Z5RC)"7(*XY'#\S@CLK4JM*"[Z_:P[%7)!ISQU[AVZ,E>D%Z03'K.\ M&X?,\E:X0] )0 50 52HCHJMQL(%[2-E.@', 2J "J "J J@ J@ J@P$!6( MR#4""I@#5*ARYH6J'6+2/OWD=A-N^X$5.;[WB33' ]?Q.-WJK,^^#K\,V'5O M.!CU!M?%7=S?V"J:OM!I@'S0I3GR09?&Y9'!R107S.;(!UV:(Q]T:8Y\T*4Y M\D&7"/X0_!D#9G/DVVNY5)5D+4KIR(!;GN4N4#ERARU0,C+N?$+O(;=>PVX7&?,[[PEM&K(E %5CE8PTTK@"8X?B *B@"@@"H@J#J*,B:(P.,'@1!U:E9HRI#)E M7UPS^;8TJ[*P;?[CZAJ)TT3%GR+G'U@ M)C3E:K\CBP8X5@O'9&*[1N34(!D5R:A%HV[=\#QR>!5-H8GM? GP EP IQ; MCRMK59GI;HPL@63%D$PCRP9&EAA98F2I'75+C2I\4+%\D#G@[52,F!0Q:X_@ M^&)\^K6X"3AO0R]U\$L)7GMXF3Y8WE-<J4C[S M';DST2,243-VAR"L]H256[_?4.BM MT\-8^,1+#;1'8WR_43J5& 4>X8>?P8 M1L!NZ66W&G)3;T;9+00:(*PFA-TAEP"4!65!65 6E 5E0=EWDJ)J4H75,%T' M?H/?ZO.[6:[+U:!=25=]/NY M=RIDA$YYZMP[=&6N2"]()SSF>C<.F>NM<(>@$X *H *H4!T56XV%"]I'RG0" MF -4 !5 !5 !5 50 5082 J$)%K!!0P!ZA0Y>0+53O$I-WZR>TFW/8#*W)\ M[Q-IC@>NXW&ZU5F?#4?CP=7?!Z/Q\&*TW9Y^9 MRK=3F*Z_^( R= E=0I?0I:'R09?FR ==(O0S1+V LCGR[;7TJDJR%J0,Y74< MW/-@H=O"@&XLWODXWD/N8GI/L;D>PM\XZ9AP'#+8!78IQRY4$@*_P"]X+]79 MI>U@'E8'5B<'JU,[D3J-!%8'[ *[WF-7JP%N@5O@%L:CX!?XI16_2G+'4*(N M(K@(+F8_-U3'W!#FAF!U8'4.&0%D.GI%!* Y%[6JC-RN&#'U8M)>RZ._7M*G M<_K*X%2,;?D<8;O_ MF*K6K)JPS@MHF@9-Y*<#G,J"$W:SX*-74%8WRG:K("R J2 PZVUL30 P%00F M(G" $^ $. '.[8>'U7:FNW\+"DT,#T'9@VW6R_08)U/624T&LCG@[4BMK"KG M;^&!>UY.';L$N=^K+UK[VZC/S+>XHKW@L3U-BVOF$?9"YR5MGGY9-Z M>P]R9Z)'/1/Y0%@05LGI$E 6E 5EX6,-(*RV\TFP5[!7ZMNK:D-J)1OV"H0% M80]/V$Y+YD "T!5T!5TQA =E05E0=B]GP&\H]59KRWFJ'AMT06\3Z=TH=SHR MIS#!'V.&#O8*]NK@X!OP(1T!O];#>JA1FQ8SZ^[HO0"<45G!H/V?;O]5P50&+:) C@$>$381-A/:A?=A^V/YB MZ1^:5U#SB(5A#_/NB(+J7_:@!K.[P,#MY.QJ\/?!Z&9P+0%T+:1\WYYILHR% M56KIPY,ZY?J)U%F=.B[>8>$9C-6=L26ITV>05@)V@]WJLUOXXVZM\/XXTRA: MA;D2Z1$S!A(P7%H8KE;YI-LHO.%"J '&:L+8$[E3DT%7T!5TS6'#X=+)<)4:W7VF!O50JS]);DZ_T26;E0]2MZ'<\M>O?_.,\;.C(=LQ!_8E3^SO,_L]<.>)R@^.)-H^JG934FV MU/7&^8RDSZ.WN^LYO)ZSH9D^=&MS;&UEB*B-G]]I9/:YDU/.K)D?>U%(&@A8 M1.^C!^Y^XVQ&ETY#QKT)G[!K/H_X[)8'K%$MLWJU=L(L;R)>=)GCV6X\H?M, M_A6'T8RO[G76_TO(2!H>1DX4!YSY=\RA[TXGWRS/IIN>.?X\\&T>AM35[#:F M?^AUA3'I5G69Y8;^QBT*5TT*_;N(14X8Q@1FGYKJ<4Z!'[NE%H8+1JV];G+MTI M6+!KWXW%)V'RE,N 6W3Q(@$)NUZ$)&S(J-FQN[VZEGTR81:+_(CN1PU>H7/K MV*I>8W2!2RV5O<6?_]2H?W8\9L>SV*5>( ELTI4_HS8'_-:*THZF5I/VQ+=W MG O9Q;4$ELAG=TXHNF7!K2!1O>A@FY0G>"OZER[A7BA48_NSN158MX[K1 LA M=\"_<8]4?1_X#]&TG'2C5+=VV=2BBVXY]Y9@HZOHP0&_S^($BOPF[!S@;^P M7")%:FW+[&'JV%/V0$"CYWQS_#AT%VL_"I\>>[M(K&!9?.CYWK$_YT'*30(M M@9?^29IEQT% [3U.>$K7./X$:-T)K;;R:+U:H31,($#>;>9XJ:M[LKZ$W,"? M)1>\[0ICSXF6P"0$/\.E[=][]-A)>BN!1P'':.H$DV,R^='BZ6'"KD93B^[D MQ^Z$3#:+R+TN4>UXQ!S[T2 O?P($[PG!$^41?$-&-& WE>L*N^<>638*V9AE MVR( F(@7PEP*8S)L*6'%J&$@/II<"_\MV MG9L WB*H$XP]?[9(XY"[V+/3('$)/#L)6:*GB($"SZ6Q%>P@D#X^)3'6MX]N5VZ*HE0T\ASZ5[7M?;"O3LT1K'(J6YH?I*/D\'Z M:II@8_Z(@),'6>OI9QQ]R?N9LT!M?C%A_V/O;<'1-KTY'?=:[.+\\'?WS M>6L/W+#KF\O+KX/SP4CLU!R.OEQC7!MU->A=C'K#K\.D*>SB"[L: M7%Y4U&U^PT_Y_WUR_^#S7II=N/"N>.&0T/DJUXXE[]58<^:L/ MTLGXY),T-JI52?CEO*XMK.L\Y)]6+UYIYRG >MHEWCGZ<4"5/J/5^+ 6?CW_ MKB;U5>8W+."SFCK+U<[GAN^/&?:X8*; X1?Z2;?921>M]X[]VL/ZX _%?^5_ MI)1J9#UY'YE)G7^B' .#[_5/M]@#O+?HC*\"+D:;9VH:>EWJ6V?!3 M'#UKHL??DA5&:%)_37Y)IT%_.-S>PR-[R_G)0SYS_#2Y"]0"M9J@=L3C*+#< M0SX2EOW'IR?JQ9%4DZG$'Z!0_14*HY<753:>7%'D8%7YM:/5FFW?<6/Q[\ * M/&I#R$I?_3#\*!9JV?74"KCJ90CVT#DJ[D3Z49?FF^^_CTU*[Z)G[QLZI+NC M6FGN94^'FLJ7//^D>/4Y8!<*;A=*U4I[+^7$W^N2P^]XE.XCF3V/,"4P)04S M);5*=2_EC]54/D(,V 78A&$O)T&IJ7S8A0,#__"G MK<@SH=W/U4 MFM)/C79SM>1]4=9;"F>9JK2V&$4K%?0:H![-1R*.SA, M0#$O*!XF<78+-:L4\IJD: -M3G)*2WV'L0S,CMEF!Y9%5\NBF*RFRU<87:J9 M\9R!Q%<\C(+8CN+DP"S;#Y/9BF[M^61%JZ/L7$5=?J["_ 3LC?F9:5<<8AF_ M48]8)P4A">,4P$% MS\.C2 M/%F-S:I(CM>UTO*M]Y;C_>+Z85HY;EDK^#@I<[8 ?!4$9Y8MBR@X#!.,$XZP!/&J8"" M8U4=VB^R]K7/J4C*TX?,OV,3?ALQ<$BJ9:"12J M,D[-F*]:J0,*JZ,J8PJKH]K+!_L ^P#[ /M0^!5WZ-(<68W- MGAC$@3_GEL<"?A^[5N0'"^9X3N188O?#8^K$:O=$O:Y0WD0+>1/JS+$=9"J@ MB[4?8%-%;&)ITBQX8FFR@(+#.,$XZ0!/&*<""HZ5J##,MQE,UE .F\L:4F*"K M[Z Y_>?A3,(@5DBUET]S>P(?I3*F8!^TEZ\PJ^[0I3FRJIE!D8'$?<>-14H# M2T^;S/D R0[.F5!G8DWE6 MK/H#G0:86.LC]*2R="?M3-?E/T6BR5*LTI#82;"BM_B-DW4VM^1BN59I2I]R^(ZRJHR*3 M /GNX&8U 7HTAQ9U4Q#V8./.9W\ M*P[%^1U)?@K].[ "C]H0LCD/V/74"KCJDX.Y3#L MNN==]+S535*]D5FTV=C/;(VBRL>R(>P"[,(FW5&OG,B<)0N[ +L NV"P7:A6 M&ON8&E=4^; +L NP"YO9!:F]UK +L NP"T;;A48;=@%V84_ W\I@Y,N$6J-2 MS:.+MDJ8RI<^'\ =<.>[W*E7#CH;90AWDD7!7R+KUN6/GR=_UYKR*F?W&3R: M71+LZ5DGVS;NY =N,6D3L[GK+A_WZU'U*'D?SBU[]?X[CQ@[,QZR$7]@5_[, M\CZSUUWW?!7TP9E$TU2.HT?8;+QH2LH\>KN[GLOZG%O-]*';=E>IME5:JK8;3ZCGK9E/#_]?*UKEF?L1_8)9R:IL6B9Q56 A\AE]Q^9Q8$^M MD#/+MHEJ$74/*8U^8O\G=D)'W"APM]=>70=\7G 0^7X JC(+:C."!! MRP(B_#YX0F/TZIA*PH9O.PD@'YQH^@QVE>_5Z@!2-D9*0SFD7 ;.S KH"D+& MD\6*4^38PD$G=FG[#3#B]ND[9Q MB2-33I8A8:/^F5J9MEA4IYD0XIGK6+>.ZT0+00(>?.-A>2FE>/#*ZKK\WG+) M#-Z)9J0<* M+^5.K^UBY!@9R)]@WE8/]FH$4+C?UIBGD[SVZ;,+B.5E$\1U% MGM0#9 *G2:5C0H9-[16ED%U?Q+<\F#&ZDT,>VO,C'@(K.V&EI3)6'(_\(%F+ MU%,&G#QCD!K("?_&77^>5L:BZ"H-KL)%F&Q$I ML?S8G*YNX5#[CP7UJ@^YC MUTHCNC"VR=FF>!S$ 5E(RV,WGG#,YWPB9&9]_LVQ.;MZ_!4K'0UNSOM71Q^3 MQ_W&/3*K=)T56>PR(#2FCOW9#W[K7]+UA41I\OP=8;K:M=?>'TZW']*^&'.0 MZWKPN\&?)G>C&-":FSR?+C.3DVI#Y<132 #:)SDAZ>V6S M;KEMQ12;)19R_9D/?NQ.V-3ZQND:+@8TD3-9G<(W(60O1]046I*S#H7]MN- M6.Q),AQ*A]O4'_ZDPI(>6.5*KUI&MPZL>_Z]%I82CUS>7EU\'Y M8#0^_GX^'%*-=&70UZ%Z/>\.LP:0J[^,*N!I<75^-!GWKPZXWX M=W!YS<87[+3_WS?7+S[/M>FE&\^*R=;SR4>I=OR0Y&N_?V8]JR^,IWB__@#/ M#V:6^VREK59-?6YF <:+UM*X@ :N:?.L./)7'Z3K?LDG:<11JY+PRP4^VW== M:Q[R3ZL7K[3S%+8\[3_L'/TX3$F?T6I^6 MJGG]7D_JJD?4-"_BLS)5RR&>U M\KEAKH=Q_=A4=K>UE%WU]D_O2;K-]E"W5#IPXY7_D>R \0-W:7Q]3A]/0S;P MQ!+1-9]'?';+ ]:HEE4[;0X WQ? 53P\: ^(IP'_B=G:AIZ7>I;9JU4'L/C^R)%0+/7ASRF4FQX'3V%Z@%:C5![8C' M46"YAWPD+'LN!W/M39.IQ#+;6*!0Q10*HY<750ISE-W5*G$$1]F]VA"'K>;8 M:K[U479=F6DM;#7'=EG8!8/M0K72/NC&>]B%W*(&V 78A2WBA3KBA6+8!5@' M6(=MTR,I;#CHB7:OR;&W3BI,?7 $&C E^9N21N4$9^P7PR[@-*\-NJK5[.(X M+]V/PM/)M9I$GG:K5GFYK0WD>9\\NA<(O_S.,6KKIZZ5?JI5FB\./(^D.9:N U5 /?;]I$WGZ^TMSA[&>]PE<#EL],AF*[TFH!BOI! M\3 9M%NH6:4E;9,4;:#-*54K59EY'PT#;IF)8*U"."7,E+H#<*WDTR&+&1I5 MW+>H)*N:"=,92'RU?MCW\I32TD^U;O7Q +)DEJ/1;#Y^H-H<1UU^CL.,Z=Q, M&)II5QPDXU!JXN-'4JHZTC0YF=A4;-8J#:EL6&!306R^>Y"%P9U06,%-M4Q_ M_E.W7JMGJFT8)X4G14SNA ((KIZ) @;4$!S:USW99+A65FTU[=*H-PHQ[:(5 M]G*;_SS$0%7J]#I50[XB#3Q4!934S < E?]0P0!939=/<^-PT&0-Y&,8:$]4 M&EUJ)1_6\$W3:,%U:6P^QGBMNOJ]Y7B_)%4(Q63 LD;U\:H*]8&&)ND8J@9OFBTIU2L-J;1_K"Y4:7+#9,%AG&"< M=( GC%,!!5=S'1[:A_8/TPG:9V',YI8=AD5%[-=6B3$)&$PD9NB^152MUK)^K8]U, %159IL4 )7_>,$ 64V73W/C M(#\# ?L ^P#[H/9R/'0)72*U8NT7@SCPY]SR:+Q^'[M6Y <+YGA.Y%ABZ/Z8 M5[':C-&JO4JJR&MHG^JJU$)FA3JS<(<8N]6DBN=@=0C85'?H 'BJ"$\L7A90 MPBCFE;W54=?Q@@J^GR:6Y/D*FA,J9@'[27KS"K^]"E M.;*JF:FQ!Q_S>QP$))7WE*114SA*]>;' M%]LW.IO.(& BSN@U(G$86:;9%>8,W0!G_>!,:):J6([U3@6QB?7. @INJF5" M,H99\(1Q*J#@6(Z']HNL?=V3,=9/%7VL\?I\9J2E[L$6J#2"!2SE@CW=39K^ MF*I6ZLC:41-06!'57C[-C0,<3JZAC(+V :4F= M+H5$4#RE.WD0&$G]Q/,NS MZ2'+G1=BF-\\4:@V2 SJ84EP;\S@]FXLB(=KW^XLR(>KNU^D"9 M+1$GFB12J)V4=NL'$QZLY*G-_V"A[SH3]J=J\I]NJT:E>J4N4^UQYV[ F1?* MVOT"TZ%6JCKY5QR*$TZ3[!/Z=V %'K4A9',>L.NI M%7!%9FIS,7<[!2\RO;"\I[CB]0WWWB$_[;$7,A05I32%N5.8X%I 5I0=J<2%NMM*6.C09G$2.#N7DRMT34;>Y1\JV6=/,% M@"KEZ>"@0?/LU[ ;"*IUY*P!S,T,Q.W*/C"LH:?Z8#KJ@??E5(C4N3+% 'RR M8O-+9-VZ_/'SY&_R$;.YZR[E^/6H>I2\#^>6O7J_?/RZZ%V2<[TY8V?&0S;B M#^S*GUG>9_9:DN4>^D;U[0H]_CNAF^M#- MN_8DC?]K6X6](JEXJT9*-&GHV6X\H9ZW9CX]_'^M:)5"[4?T"V8E2ULS[D4A M6]7QBWQ&W[%Y'-A3*^3,LFT_]B+J'E(:_<3^3^R$CKA1N,S8%E\Y$[J)<^?0 M#1POLKQ[1R#'"D,>I)'/03=F^?FIWN8[:XJ#\8B!\FTHF= MXR3>F15,_D*-][[13_Q@P>A"(?*::&Q"?5%YCRI;T:-P=*@K1X/#*^+O\WG+)&M^) M9J3(+R=&]:36?+8%1]A+HI S2WYFQ[-X:5]3MM!/K,='4TLLUTUNTWGITTF/0V7WEI/XB9\:C?8S6W[OD:#"Q>B@A#6/>M8GAQ-:9 -(*H/9M3/_0:[B>G0Q*4SF#LN9Z!-!7AP&O83J>+\,0 MBOFI!\BY3%\V#&Z$X.!6.>'W%@93>LM%3&BN-1A$$6.;6J M :>8(T@MRH1_XZX_9TOCP=,X.ER$R79*NL#V9W-WD08K?,:#^]3.WR>&6@3O M86Q3&)/B<7!SWK]*[O!;__(*B-H)46WE$/5J7'5"2'@$F<5HI!?<\V=!S@/= MA[.)_Y :)=L*@H5 4#KT6C-*KX=[3OJ3ZYCN2:.KF#!<69^"_'NO?,T['[63Q0!A+;#*1H(D[X2 MG'P@*HE_?VIUO]>4URUX?/"SH?4\H M(&2LGM6G*)"3SV ]BWHAT0RXO@O7 M.\IQ?)@7MU)S)B9(M#9\*7TRO)U,H= M#Y9Q3'*#(+W;:@9PE7 _62;<6]1I%OFGY9W]. K)JB8#UU)BV/PXI/?A1_9 MCZNWJ^5.JPL8[P3C$^5@O!8VB(EH <&(_"0!>4973D/&/>&=K_F<0N!;%G[N^?%M MP*U_'UMWU.)/EOM@+<*C#:3-0+;OI"X\]?2SCM^DS[-:9CL;],87(]8?]OXV M'%W3J]-1G_4NSB]/1_]\WMH#-^SZYO+RZ^!\,!J??F7#T9>+J_/3\?!BE&NC MOOQ3'IWU:KTJ_>-DGN[B9OSUXN)O[&K0NQCUAE^'F7?(VJ^?6>?DUXXG MUL^2]^NW]_Q@9KG/%I5KU=2@9^:]7K0V]56U*LFU7*BV:1AES4/^:?7BEO2JG7$#'>]#QEW\L M:^I R3DI62XM/'N6LR__&!40!*:=6G36_P=;.N<":G,[2C>(;Q,_%A-JNW!Z M[SK=?S!PIUP_V?UHX.^(MW>E*+1UTGB&Y1(:-2O5#V()L%EIJ;); M$(K>AZ+_7XTT#0T;K.'6DLJM8E)9J:G&Y1)G7:QGFC[M>$!9E2IK!AU#5L@* M62$K9#5-5J6"*=.56J2@";K$&CQR:@#S LL'WVJ.?$6SQV1^8]=E_^16P)3* M;=U/63OD5&R$!+%*J(A;WJ)35#*%Q4#,!S;T[(!;(;(V()]N\IF60W7%YWZ@ M1>4WW5&LWT'V>Q,JL]BL4>GN<.8Q#J+7G5.0#_)!/LA7!/ERC3PS$.SR.Z>M MKQ_.7OJI5FF>G+#;Y5EPRX-R'\_HV=[/AO'\!STESO)YXZ"6SCQ:*2(Y\9YN M5%"/O7&I;QE9]Q\?MBK-MH3B$ +"1$,^R ?Y()]*\ND> EZM5R19'OA-85_W M\4#"QZ!/_JRT':.^I*0+XCU-X[UJI8UX3RE 03[(!_D@'^0K8+PW7"LYMXKV M&O4&HCT5P*5_M%>KO#JV&]$>K#'D@WR0#_+I)I_NT=YXK:"PJ&[ZB^N':EGRN_13JZE0Y-=$Y*=OY%>MU&7.U47D!\L,^2 ?Y(-\*LFG M>^0WB -_SBV/!?P^=JW(#Q;,\9S(L41)[L=)P-6"<*NF4!S80ARHR=8SOXU5-KST4;4IW745T/4 MIQ*@(!_D@WR0#_+I%O7MP0W^'@;' M'T>$!=*__@%9J5JI[G(@]),6=A$G*_Q^+"8&(1_D@WR0#_(AAOOKT+/]&6<4 MDK%;[O$[)YG5"^?<=BR7.1&?I?L\G,<9/W%IP._\8"9BNW:]_AC<%=2?ZA[3 MU2MUF9-5$-,IA$'(!_D@'^2#?(CI_GJ:'+V,PA^[5&AJS/]@$S^^=?E.)9KT MJPRR<3>H6SJD5JNT94Z/>5=T%!H' 8-NI?4!*(!\FLFG5&WD9>)@O4I7FJ[4 \JZ<[)^32BM)4JK5*E7,.D$^W>1+ J5?(HN8^?AY\G>M/:^. M'EN7L4O-?QGP).\=C]I.XC6S"?5$X'/,OO@!M<-CO3@(N&RD!VF[]@\#NRI%7)FV;8? M>Z)D!RF.?F+_)W9"1]PH7&[S%5\Y J?.G9./^.W3E_T(5KWXK"()7O'?+RC%I;0;* $*PK",$K/@]XN$18& 6Q'<4!R5H6 M.'FL"2TP$*U5#4R/!"> ^+:3H/+!B:;/L >T[(J6AH)H63=8<8H96P2GB5F2 M/!4T?2LN_^1$)(Q-S[E(S)\_YP)_9+[X'W/NA;S,/!Y)/D;$!XWZ9VIGVN95 MK4OF.M:MXSK10A" !]]X*+ OY!1/7IE=E]];+MG!.]&.%/]E82I_.JD]E4=* M:$+&F3]FOMCQ3)RL[WQ;_B8Y9/7QT=02RW63VW1:J[M4&#MU0W_9!NKKQ-RG M!VTEY3J3ZQN-IWJ<0J![CR05QET/-:QYL[/^7T(66F0+2"Z'NNAT\DT<.C9A M9XZ?'#P6AN+AMS']0Z\K,"R[&9:F@H9ES0T)N#O+FF1KR([GA/2$7,_KDQ%H M;&JQX(7KBQ"7!S-&=W(H&/+\B ,ON^*EI39>THHE[M*^!IQBD""U+!/^C;O^ MG"V-"$]CV7 1)N?@T 6V/YN[BS1XX3,>W*<6/RF&D@3086Q36)-B M8SGI3ZYCNF>P8#&!MI).6&PV;9%\G&P97LUYD(O+2H0Z0=_ZN:+^+O M__FO7V[]R>*O__>_?IE&,_>O_Q]02P$"% ,4 " #=,65/TAV4N[XE ; M+P$ $ @ $ 83 Y,S R,#$Y."UK+FAT;5!+ 0(4 Q0 M ( -TQ94\^LY\\/P0 /P8 0 " >PE !B9'@M,C Q M.3$Q,#4N>'-D4$L! A0#% @ W3%E3TN:^2HY 0 >@( !0 M ( !62H &)D>"TR,#$Y,3$P-5]C86PN>&UL4$L! A0#% @ W3%E M3W%7I#-2"0 !$\ !0 ( !Q"L &)D>"TR,#$Y,3$P-5]D M968N>&UL4$L! A0#% @ W3%E3\<4X!!=#P );4 !0 M ( !2#4 &)D>"TR,#$Y,3$P-5]L86(N>&UL4$L! A0#% @ W3%E3U?; M5--*"0 [%8 !0 ( !UT0 &)D>"TR,#$Y,3$P-5]P&UL4$L! A0#% @ W3%E3]ZN+KVHQP __89 !$ ( ! K4TX &5X.3DQ,#DS,#(P,3DN:'1M4$L%!@ ' < PP$ "H6 0 $! end XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}

Cover Page Cover Page	Nov. 05, 2019
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Nov. 05, 2019
Entity Registrant Name	BECTON, DICKINSON AND COMPANY
Entity Central Index Key	0000010795
Amendment Flag	false
Entity Incorporation, State or Country Code	NJ
Entity File Number	001-4802
Entity Tax Identification Number	22-0760120
Entity Address, Address Line One	1 Becton Drive,
Entity Address, City or Town	Franklin Lakes,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07417-1880
City Area Code	(201)
Local Phone Number	847-6800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $1.00
Trading Symbol	BDX
Security Exchange Name	NYSE
Depositary shares \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A
Trading Symbol	BDXA
Security Exchange Name	NYSE
Notes 1.000% due December 15, 2022 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due December 15, 2022
Trading Symbol	BDX22A
Security Exchange Name	NYSE
Notes 1.900% due December 15, 2026 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.900% Notes due December 15, 2026
Trading Symbol	BDX26
Security Exchange Name	NYSE
Notes 1.401% due May 24, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.401% Notes due May 24, 2023
Trading Symbol	BDX23A
Security Exchange Name	NYSE
Notes 3.020% due May 24, 2025 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	3.020% Notes due May 24, 2025
Trading Symbol	BDX25
Security Exchange Name	NYSE
Notes 0.174% due June 4, 2021 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.174% Notes due June 4, 2021
Trading Symbol	BDX/21
Security Exchange Name	NYSE
Notes 0.632% due June 4, 2023 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.632% Notes due June 4, 2023
Trading Symbol	BDX/23A
Security Exchange Name	NYSE
Notes 1.208% due June 4, 2026 \| NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.208% Notes due June 4, 2026
Trading Symbol	BDX/26A
Security Exchange Name	NYSE